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Introduction 1
1. Introduction 
1.1. Colon cancer 
Colorectal cancer is the third leading cause of cancer-related deaths in the United 
States when men and women are considered separately, and the second leading 
cause when both sexes are combined. It is expected to cause about 49,960 deaths 
(24,260 men and 25,700 women) during 20081. Despite intensive ongoing research 
patients show rapid progression and chemoresistance stays one of the major 
hindrances for successful therapy. 
1.1.1. Low passage colon cancer cell lines 
The appropriate model system is a key implement in cancer research. As cancer is a 
complex system and an attribute of cancer cells is their genetic instability, in vitro 
cancer research often does not represent sufficiently the in vivo conditions. In 
contrast, tissue culture models of colon cancer often do not fulfill all requirements for 
efficient in vitro research and working with primary cultures is mostly limited by 
generation of sufficient material for larger screening experiments or e.g. proteomic 
approaches2. Low passage cancer cell lines recapitulate properties of original tumor 
cells more closely than commonly used standard cell lines that experience artificial 
selection processes and mutations over years of passaging. Therefore eight human 
low passage colon cancer cell lines originating directly from the clinic have been 
generated in the lab of Prof. Wagner. These cells still closely resemble the 
phenotypes of their corresponding tumor cells and have been extensively 
characterized concerning their morphology, different cellular marker expressions and 
their molecular caryotype3.  
1.1.2. Threedimensional culture systems 
Even if low passage cancer cell lines provide already a better in vitro model than 
classical well established cancer cell lines, loss of tissue-specific properties is 
common for cells grown in twodimensional (2D) monolayer cultures. 2D in vitro 
cultures do not reflect aspects of cell proliferation, differentiation and cell 
environment, i.e. cell-cell contacts and different growth areas of tumors in vivo 
concerning microenvironmental properties. However, these parameters as well as 
paracrine and autocrine communication play an important role in cancer therapy of 
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solid tumors and the failure of many therapeutic approaches is due to structural 
properties of tumors in vivo. Threedimensional (3D) cultures are widely used as 
avascular tumor models for metastasis, invasion and for therapeutic screening. In the 
past 10 years a variety of 3D in vitro culture systems has been established4;5. 
One possibility to model 3D cell growth in vitro is the generation of multicellular 
spheroids (MCS)6;7 . Similar to tissue morphogenesis in vivo, complex cell adhesion 
and differentiation processes contribute to the formation of spheroids. Especially 
adhesion factors such as integrins and cadherins play a pivotal role in formation of 
loos aggregates and their maturation towards compact spheroids8. Regarding 
transport of nutrients, oxygen or waste and penetration of therapeutic agents, MCS 
can simulate the situation of avascular tumors with diffusion limitation of about 150-
200 µm9. MCS with a diameter > 500 µm commonly displays a layer-like structure 
comprising a necrotic core, surrounded by a layer of quiescent cells which is finally 
surrounded by a proliferating rim10. Several cell types can recapitulate their 
polarization and form differentiated tissue like structures e.g. lumen containing 
spheres11 and adaptation processes of tumor cells to low oxygen and nutrition supply 
as well as acidic pH can be observed in inner layers of many spheroids12;13. MCS can 
be generated by different methods often based on prevention of cell adhesion to the 
culture surface or by individualizing of cells. Popular techniques include the hanging 
drop method, surface coating with non-adhesive material (liquid overlay technique), 
spinner flask cultivation or monoclonal growth in agarose4. 
1.1.3. Proteomic profiling of multicellular spheroids of low passage colon 
carcinoma cells 
Lars Gaedtke established spheroid cultures of the low passage colon cancer cell line 
COGA-5 and COGA-12 by liquid overlay technique6 in his PhD work (Figure 1).  
 
 
 
 
 
 
Figure 1: Mulitcellular spheroids of (A) COGA-5 and (B) COGA-12 cells14.  
He analyzed the proteome of both 3D cultures versus their corresponding 2D 
cultures. 2D gel electrophoresis (2DE) followed by peptide mass fingerprinting 
A B
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identified three differently expressed proteins in COGA-5 spheroids (acidic calponin, 
hydroxyprostaglandin dehydrogenase, lamin A/C) and two in COGA-12 partly 
compact aggregates (two isoelectric variants of acidic ribosomal protein P0) 
compared to the respective monolayer cultures (Table 1). The lamin A/C spot 
showed a lower molecular weight in the 2D gel (30 kDa) than expected for full length 
lamin (Figure 2). Purpose of the current work was to clarify the role of lamin A/C 
fragmentation in MSC of low passage colon cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: 2D gel of mulitcellular spheroids versus monolayer cultures of COGA-5 cells. Differentially 
regulated spots are marked by an arrow. The spot representing the fragmented lamin A/C is 
highlighted15. 
 
Spot no. Identified protein protein regulation 
5-A Acidic calponin down 
5-B 15-hydroxyprostaglandin dehydrogenase up 
5-C Lamin A/C up 
12-A Acidic ribosomal protein P0 up 
12-B Acidic ribosomal protein P0 up 
 
Table 1: Proteins differentially expressed between multicellular spheroids of cell lines COGA-5, 
COGA-5L, COGA-12 and corresponding monolayers15 
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1.1.4. Chemoresistance to 5-fluorouracil in colon cancer 
5-Fluorouracil (5-FU)-based chemotherapy regimens are still the standard treatment 
for colon cancer in both adjuvant and palliative disease settings16. 5-FU is a 
fluorinated pyrimidine that acts primarily through inhibition of thymidylate synthase 
(TS), which is the rate-limiting enzyme in pyrimidine nucleotide synthesis17. As a 
pyrimidine analogue, 5-FU is converted to fluorodeoxyuridine monophosphate 
(FdUMP), which builds a stable complex with TS, and thus inhibits deoxythymidine 
monophosphate (dTMP) production18. As dTMP is essential for DNA replication and 
repair, its depletion finally induces cell cycle arrest and apoptosis19;20. Despite 
inhibition of TS, 5-FU can also be miss-incorporated into RNA and DNA instead of 
the nucleotides uracil or thymidine. Following accumulation of 5-FU in the genome 
causes cytotoxicity in mammalian cells21. Recent studies have demonstrated that 
also RNA-based effects of 5-FU, especially in rRNA maturation and mRNA splicing 
play a role in the cytotoxic effect of the drug22;23.  
Major hindrance in successful chemotherapy is the occurrence of drug resistance. 
This is responsible for treatment failure in >90% of patients with metastatic cancer24. 
Overcoming drug resistance is one of the main challenges in cancer research today. 
Meanwhile, understanding the mechanisms by which tumors become resistant to 5-
FU is an essential step towards predicting or overcoming the resistance. Several 
mechanisms such as high-level expression of TS25, increased activity of deoxyuridine 
triphosphatase26, methylation of the MLH1 gene27, and overexpression of Bcl-2, Bcl-
XL, and Mcl-1 proteins have all been described to be possible mediators of 5-FU 
resistance28. This leads to the suggestion that resistance is a complex process often 
composed of multiple pathways playing together. 
Therefore appropriate cancer models and more global approaches such as 
microarray and proteomics techniques might lead to better understanding of the 
underlying mechanisms. 
1.1.5. Chemoresistance of low passage colon carcinoma cells towards 5-
fluorouracil treatment in vitro 
In order to study protein expression profiles in chemoresistant colon cancer cells 
compared to corresponding non resistant control cells Lars Gaedtke had established 
in vitro 5-FU resistant monolayer clones of low passage colon cancer cell line COGA 
12 (Figure 3). 
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Figure 3: Chemosensitivity of three month 5-FU pretreated COGA-12/G6 cells towards 5-FU in 
comparison to wildtyp COGA-12 cells15.  
 
He compared the protein expression profile of these cells (COGA-12/G6 cells) with 
the non resistant COGA-12 cells and long term passaged non-resistant COGA-12/ 
NO cell by 2DE (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: 2D gel of 5-FU resistant COGA-12 cells (COGA-12/G6) compared to non resistant COGA-
12 cells15. 
 
The differential regulated spots have been identified by MALDI-TOF MS (Table 2). 
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non resistant COGA-12 cells. The current work further focused on the role of Hsp27 
in 5-FU chemoresistance. 
 
Spot no. identified protein protein regulation 
G6U-1 Cytokeratin 18 up 
G6D-1 Aldehyde Dehydrogenase 1B1 down 
G6D-2 Heat shock protein 27 down 
G6D-3 Heat shock protein 27 down 
NOU-1 Maspin up 
 
Table 2: Protein identification of differential expressed spots in COGA-12/G6 versus COGA-12 cells 
1.2. Prostate Cancer 
Prostate cancer is the second leading cause of cancer related death in the United 
States in 2008 (Cancer Statistics ACS) and the most common newly diagnosed 
malignancy in the western world29. Angiogenesis is a key requirement for tumor 
growth and metastasis formation in prostate cancer and anti-angiogenic therapy 
regimens have been used in several clinical trials especially in hormone resistant 
prostate carcinoma (HRPC) where the prognosis for patients is poor and patients 
typically show rapid tumor progression30-32 
1.2.1. Metronomic Cyclophosphamide Therapy 
The maximum tolerated dose (MTD) is the classical administration regimen of 
cyclophosphamide (CPA) and other chemotherapeutic drugs in order to exert 
cytotoxicity to fast dividing cells including the tumor cells and tumor vasculature 
endothelial cells. This administration schedule requires long treatment-free intervals 
as it is characterized by high toxic side effects. During treatment-free periods the risk 
for selection of resistant tumor cells due to genetic instability of cancer cells persists 
and furthermore vascular endothelial cell in the tumor area have the ability to recover 
and promote tumor angiogenesis of eventually surviving tumor mass resulting in fast 
re-growth of tumors leading to therapy failure33;34. Beside these risks, MTD always 
has severe side effects on the whole organism. 
In the last decade administration of chemotherapeutics has been developed towards 
a more compressed schedule using much lower doses enabling shorter treatment 
gaps35. Browder et al showed that weekly applied low dose cyclophosphamide could 
improve antitumoral activity of CPA due to cytotoxic effects on tumor endothelial 
cells34. Hanahan and co-workers introduced the term “metronomic” for this kind of 
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longterm low-dose treatment regimen and demonstrated its antiangiogenic 
properties36. Even if the mechanism of antiangiogenic impact of this therapeutic 
scheme is not fully understood yet, several aspects may be involved: 1) due to the 
dosing dividing tumor endothelial cells are affected more direct and selectively 
compared to other cell types37; 2) metronomic chemotherapy seems to directly target 
bone marrow derived endothelial progenitor cells38;39 preventing their attraction to the 
tumor; and 3) this therapy scheme modulates the level of angiogenic cytokines and 
therefore indirectly influences the balance of pro-and anti-angiogenic factors40-42. In 
vitro evaluation showed decreased proliferation and migration capability of cultured 
endothelial cells in the presence of activated CPA34. Further studies confirmed 
decreased angiogenesis in matrigel plug studies43, increased apoptosis of 
proliferating endothelial cells in the tumor bed and significantly influence of functional 
tumor blood flow44. Currently, metronomic CPA therapy is a promising approach in 
the clinic for docetaxel-resistant HRPC. Even as follow up therapy for already 
docetaxel-resistant HRPC, metronomically scheduled CPA reveals encouraging 
therapeutic response and has the potential to increase patients’ life quality and 
survival42. 
1.2.2. Chemoresistance to antiangiogenic therapy 
Nevertheless recent studies have demonstrated that this therapeutic approach does 
not come up to its expectations. The effectiveness of antiangiogenic schedules as 
single agents was low in the clinic and resistance towards this therapeutic scheme 
also shapes up as a problem45;46.  
As tumor angiogenesis is a complex process based on the interplay between tumor 
cells and endothelial cells, resistance mechanisms towards antiangiogenic therapy 
can be multifaceted and at different levels of interaction47. As the therapy regimen is 
not designed to kill the tumor cells directly, classical detoxification based resistance 
mechanism such as upregulation of ATP- binding cassette (ABC) transporters 
become less relevant48. 
More complex mechanisms based on cell-cell communications, such as cytokine 
expression, or survival mechanisms of tumor cells based on metabolic adaptation 
processes, e.g. tolerance towards hypoxia, may be important in this kind of 
resistance49-51. The phenomenon that tumor cells can imitate endothelial cells which 
results in functional vessel structures and tumor blood supply without any endothelial 
cells involved is described as vasculogenic mimicry. Vascular mimicry was first 
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discovered in melanoma and has been observed in many other types of tumors such 
as breast, prostate52;53. Tumor cells can also become independently of angiogenesis 
by growing along existing vessels without evoking an angiogenic response. This 
process has been defined as vessel co-option. First evidences for this phenomenon 
have been described by Holash et al in 1999 in a C6 glioma model in rat brain and it 
has been shown that tumors can evade anti-angiogenic therapy with a vascular 
endothelial growth factor receptor 2 (VEGFR2) antibody by increased vessel co-
option54;55. 
Hypoxia induced by anti-angiogenic therapy can also lead to recruitment of bone-
marrow derived cells (BMDC). BMDCs are a heterogeneous population including e.g. 
vascular progenitor cells and pro-angiogenic monocytes which participate in 
resistance to antiangiogenic treatment either by direct incorporation into functional 
vasculature or by secreting cytokines, growth factors or proteases. Clinical 
investigations with anti-VEGF therapy in patients having glioblastoma multiform 
(GBM) showed that in therapy evasive tumors accumulation of endothelial progenitor 
cells at the tumor margins occurred and enabled tumor revascularization56. 
Furthermore pericytes can be recruited to the tumor in case of anti-angiogenic 
therapy either by a kind of SOS-signal of endothelial cells or by tumor cells 
themselves. It could be observed that vessels tightly covered with pericytes are less 
sensitive towards antiangiogenic treatment. Even tumors which stay with only few 
vessels left can survive as pericytes protected endothelial cells in these vessels resist 
the antiangiogenic treatment. Beside a mechanical shielding effect on endothelial 
cells probably secreted cytokines of the pericytes such as e.g. VEGF or survival 
factors can protect the endothelial cells towards the therapy57;58. 
Hypoxia plays a major role in a variety of drug resistance mechanisms in solid 
tumors. It plays an important role on tumor microenvironment but also on tumor cells 
themselves. Otto Warburg has described already in the1920s that tumor cells mainly 
gain their energy from glycolysis instead of the oxidative respiration which enable 
these cells to better tolerate hypoxic conditions in solid tumors59. 
In last few years, cancer stem cells (CSCs) have been identified in almost all types of 
cancers60. CSCs have the ability to generate tumors that recapitulate the original 
tumor when xenotransplanted into animals, whereas the remaining non-CSC tumor 
bulk often can not61;62. These cells have also been linked to chemoresistance in 
several aspects63. 
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In respect to cyclophosphamide therapy these cells have shown overexpression of 
ALDH1 an enzyme involved in the detoxification process of cyclophosphamide64. The 
role of CSCs in antiangiogenic therapy is not well understood yet, but a positive 
feedback loop between CSCs and the vasculature has been observed. CSCs often 
express high levels of VEGF and can thus initiate angiogenesis65. Stem cell factor 
can activate microvascular endothelial cells in vitro and induce angiogenesis in 
vivo66. Hypoxia can enrich the CSC fraction in tumor which than leads to a more 
aggressive and resistant tumor phenotype67. 
1.2.3. Proteomics and genomics in drug resistance 
In the pre-proteomic era mostly one protein was identified to play a role in 
chemoresistance and was declared to be responsible for the phenomenon of the 
resistance towards a special drug e.g. thymidylate synthase in 5-FU resistance. 
However, failure of many anti-resistance strategies in the clinics have demonstrated 
that resistance in vivo is a far more complex phenomenon than modification of e.g. 
single drug metabolizing pathways68. Especially resistance towards antiangiogenic 
therapy were tumor/ host interaction becomes important a more global approach e.g. 
by proteomics or genomics, or even combination of both techniques, could reveal 
novel resistance mechanisms and their interplay in mediating the drug resistant 
phenotype69;70. In the last few years several lists of proteins related to different 
cellular pathways such as stress response, cell metabolism, protein biosynthesis, cell 
cycle and apoptosis have been related to drug resistance by proteomics and 
genomics71-73. Different proteomics techniques as well as the bioinformatic platforms 
have been optimized over the last decade and can be combined to obtain maximum 
output of information. Most prominent techniques are 2D-electrophoresis (2DE) or its 
optimized form the 2D-differential in Gel electrophoresis (DIGE) and mass 
spectrometry based techniques such as MALDI-TOF and LC-MS.  
In parallel the analysis of gene expressed has also be optimized and microarray 
based gene expression profiling has become a standard technique applied in all 
areas of biomedical research74. The key point of informative output from gene 
expression as well as proteomics is bioinformatic processing of the data. During the 
last year many bioinformatic applications for so called “data mining” have been 
developed which enable the combination of different data sets, pathway analysis of 
the obtained data and their integration in literature database searching75.  
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However, relevance of the data obtained by proteomics and genomics for their 
involvement in disease associated pathways in vivo has come more in the focus of 
attention. In the field of cancer chemoresistance, clinical data provide disappointing 
results in case of in vitro identified protein candidates for their relevance in vivo76;77. 
Therefore it has gained importance to create chemoresistance model system which 
better reflect the situation in vivo and to validate candidates obtained from in vitro 
studies in the appropriate tissue material. 
1.2.4. In vivo resistance of prostate cancer xenografts towards metronomic 
cyclophosphamide therapy 
In order to address this question of a better model of chemoresistance, Dr. Guenther 
has established an in vivo resistant prostate cancer xenograft model towards 
metronomic CPA therapy in SCID mice78. Male SCID mice bearing subcutaneously 
implanted PC3 human prostate carcinoma tumors were treated with metronomically 
scheduled CPA (120 mg/kg every six days). CPA treatment was started on day 11 
after tumor implantation when tumors reached an average volume of 37 mm3. 
Metronomic scheduled CPA treatment resulted in a significant tumor growth delay. 
Tumor volume of treated mice was constant at <100 mm3 up to day 50 after the 
tumor cell implantation, whereas tumors in the control group exhibited a tumor 
volume doubling time of 2.5 days. Around day 50 after tumor implantation tumor 
volume began to increase in the CPA treated group with a tumor doubling time of 9 
days despite ongoing treatment (Figure 5A, B). Metronomic scheduled CPA therapy 
was well tolerated indicated by constant animal body weight up to day 67 after tumor 
cell implantation. Further CPA treatment resulted in significant loss of body weight 
observed in all CPA treated animals (data not shown). Treatment was stopped and 
animals were sacrificed when average loss in body weight reached 20 %. 
For further investigation tumors were collected and subject to histological analysis. 
Further on, tumor cells were extracted in viable form from tumor tissue for 
characterization and cell culture experiments (Figure 5A). 
For further investigation of the drug resistance mechanism, the effect of 4-
hydroperoxy-cyclophosphamide (4-HOO-CPA) on survival of parental PC3 cells and 
reisolated PC3-D3 and PC3-D4 tumor cells was investigated in vitro. 4-HOO-CPA is 
rapidly converted to 4-hydroxy-CPA (4-HO-CPA) in aqueous solution and can be 
considered equivalent to 4-HO-CPA under experimental conditions79. Incubation of 
parental PC3 cells (PC3-wt) and reisolated tumor cells (PC3-D3 and PC3-D4) at 20 
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to 50 µM 4-HOO-CPA significantly reduced cell survival after a three days treatment. 
The reisolated PC3-D3 and PC3-D4 cells exhibited comparable sensitivity to the 
PC3-wt cells in the monolayer system (Figure 5C). Reisolated cells were not able to 
manifest their acquired in vivo chemoresistance in an in vitro monolayer cell culture 
model. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The PC3 chemoresistance mode: (A) Schematic view. (B) In vivo resistance of PC3 
xenografts in SCID mice. (C) Chemosensitivity of reisolated PC3 cells in vitro 
 
In order to analyze the influence of CPA therapy on tumor histology, expression of 
vascular markers and functional blood flow at the first therapy end point, Dr. 
Guenther characterized PC3 tumors in terms of histology and immunohistochemistry 
with focus on vascular markers (Figure 6) The tissue structure in untreated PC3 
xenografts was compact and only small areas of condensed and fragmented cell 
nuclei could be detected (Figure 6A). In contrast, CPA treated tumors exhibited 
larger areas of condensed and fragmented cell nuclei, indicating cell death (Figure 
6B). To evaluate possible reasons for acquired resistance towards CPA treatment, 
PC3 tumors were analyzed for immunohistological changes. Considering the 
antiangiogenic metronomic schedule of the CPA treatment, immunostaining was 
focused on vascular markers such as CD31 and mouse specific laminin. Additionally, 
tumor blood flow was visualized by intravenously applied Hoechst 33258 dye as a 
tracer. Antibody staining for murine CD31 was performed to detect mouse endothelial 
cells and combined with staining for laminin, which is the major component of the 
vascular basement membrane. Co-localisation of laminin and CD31 positive 
endothelial cells remained unchanged (Figure 6C, D). No statistically significant 
changes in total count rate for CD31 positive events, representing functional as well 
as not functional vessel structures, could be detected in CPA treated tumors in 
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comparison to non treated control tumors (Figure 6E). However, long term treatment 
resulted in increased number of vessel structures without a detectable capillary 
lumen attended by decreased Hoechst 33258 fluorescence signal within the tumor 
tissue (Figure 6C versus 6D; 6E). Decreased tumor blood flow indicates 
antiangiogenic activity of the treatment regimen at this time point. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Histology of subcutaneous (A) untreated versus (B) CPA treated PC3 xenografts (H/E stain) 
Vascular marker expression in untreated (C) and CPA treated tumors (D).CD31 (green) and laminin 
(red). Hoechst 33258 dye (blue). Vessel structures with detectable lumen are indicated by filled areas 
of the circular diagram (E). Quantification of functional blood flow by Hoechst 33258 fluorescence at 
the treatment endpoint (open symbols) (E). For quantification of CD31 count, lumen containing vessel 
fraction and blood flow (four sections per tumor) were examined and three areas per section were 
randomly selected for image analysis78. 
1.3. Aim of this thesis 
Drug resistance is still the major drawback for successful cancer therapy in various 
types of tumors and mechanisms of resistance in vivo are poorly understood. A better 
understanding of biological pathways of chemoresistance in combination with well 
evaluated biomarkers for resistance would provide a better basis for the design of 
suitable therapeutic approaches to overcome tumor resistance in future. Therefore 
main focus of this thesis will be to address the complex issue of chemoresistance in 
vivo by a proteomic and genomic approach in order to identify new relevant 
biomarkers. Furthermore the role of selected candidates for their involvement in 
chemoresistance and 3D tumor growth should be specified. In detail this question 
should be addressed by the following steps: 
The implication of 3D tumor growth in cancer resistance of solid tumors has been 
described in various studies80-82. Lamin A/C fragmentation has been previously 
identified in our group to be specific for 3D cultures of low passage colon cancer cell 
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in comparison to 2D monolayer cultures. In order to better understand biological 
mechanisms behind 3D tumor growth, the specific aim of this work should be to 
clarify the role of Lamin A/C fragmentation in 3D tumor growth. 
In parallel siRNA technology should provide information about the functional role of 
Hsp27 in chemoresistance of low passage colon cancer cells (COGA-12) towards 5-
FU15. 
In order to identify biomarkers with high impact for in vivo relevance proteomics and 
genomics technology should be combined for the analysis of in vivo relevant 
resistance mechanisms in a xenograft model of prostate cancer cells manifesting 
their resistant phenotype only in vivo. Therefore protein expression of reisolated cells 
from resistant tumors towards metronomic cyclophosphamide therapy in vivo78 
should be compared to their non resistant wild type as well as to in vivo passaged 
control cells (reisolated from sensitive tumor, which have not been treated with CPA 
in vivo). Furthermore, to address the complexity of in vivo resistance proteomics data 
should be supplemented by gene expression profiling of corresponding tumors by 
microarray analysis (Figure 7). 
 
 
 
 
 
 
 
 
 
 
Figure 7: A proteomic and genomic approach to in vivo chemoreistance in metronomic 
cyclophosphamide therapy 
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2. Materials and Methods 
2.1. Cell Biology Methods 
2.1.1. Cell culture  
Cell culture media, antibiotics, fetal bovine serum (FBS) and trypsin/EDTA solution 
were purchased from Invitrogen GmbH (Karlsruhe, Germany). 
Human low passage cell lines COGA-1, COGA-2, COGA-3, COGA-5, COGA-5L, 
COGA-10 and COGA-12 were obtained from colorectal cancer patients and resemble 
the phenotype of the original tumors as previously described3. Cell lines COGA-1, 
COGA-5 and COGA-10 exhibited epithelial-like, COGA-5L and COGA-12 piled-up, 
and COGA-2 and COGA-3 rounded-up morphology. Only 5 - 10 passages after 
harvesting the primary tumor cells from the patients were required for the generation 
of such low passage cell lines. The cell lines were grown in RPMI 1640 medium 
containing 10 % serum (Invitrogen, Karlsruhe, Germany) at 37° C in 5 % CO2 
humidified atmosphere.  
PC3 human prostate carcinoma cells (CRL1435) were cultured in RPMI 1640 
medium supplemented with 10% FBS. Cells were grown at 37°C in 5% CO2 in 
humidified atmosphere. 
2.1.2. Multicellular spheroid culture 
Multicellular spheroids were generated using the liquid overlay technique as 
described previously83. Briefly, 24-well culture plates (Nalge Nunc International, 
Naperville, IL, USA) were coated with 300 µl of 1 % SeaPlague agarose (Biozym, 
Hess, Germany) in serum-free growth medium. In each well 105 cells from a single-
cell suspension were added to total volume of 1 ml growth medium containing 10 % 
serum, and multicellular spheroids were allowed to form over 24 to 96 h. In order to 
inhibit caspases-6 induced lamin A cleavage in spheroids, the caspases-6-specific 
inhibitor Z-VEID-fmk (50 µM) was added to the media previous to spheroid formation. 
Spheroids were grown 24h before cell lysis followed by western blot analysis. 
Controls were grown in media containing appropriate amounts of DMSO. 
Materials and Methods 15
2.1.3. Oxygen and serum deprivation 
For oxygen deprivation cells were incubated in an oxygen-free N2/CO2 (95%/5%) 
atmosphere for 24 h. For serum deprivation cells were incubated in RPMI 1640 
containing different percentages of fetal calf serum (0%, 2%) for 24 h. In order to 
block lamin cleavage by inhibition of caspases, cells were preincubated 30 minutes 
prior to hypoxia with the inhibitors z-VAD-fmk (10 or 50 μM) the specific caspase 6 
inhibitor z-VEID-fmk (50 μM). Control cultures were grown in RPMI containing 10% 
fetal calf serum.  
2.1.4. In vitro chemotherapy 
COGA cells were treated with either Camptothecin (Sigma-Aldrich, Taufkirchen, 
Germany), (1-25 µM) or 5-fluorouracil (Sigma-Aldrich, Taufkirchen, Germany), (5-20 
µM) for three days before cell lysates were subject to western blot analysis, MTT or 
Hoechst assay. Controls were treated with the appropriate amounts of DMSO. 
2.1.5. Cell viability, Apoptosis and Proliferation  
2.1.5.1. MTT Assay 
In order to determine metabolic activity of the cells the (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay was used. Therefore the culture 
medium in each well was replaced by 300 µl of fresh culture medium containing 
0.25% MTT (w/v) followed by incubation for 3 h at 37°C. MTT is converted to a 
colored, water insoluble formazan salt by the metabolic activity of viable cells. The 
culture medium was then removed and cells were frozen at -80°C. After thawing the 
cells, 300 µl of DMSO was added to dissolve the insoluble formazan salt and 
absorbance at 590 nm was measured using a SPECTRAFluor Plus plate reader 
(Tecan, Grödig, Austria). Reference absorbance at 630 nm was subtracted from the 
absorbance at 590 nm for each well. 
2.1.5.2. Hoechst Assay 
In order to determine cell proliferation, DNA content of cells was measured by 
staining DNA with Hoechst 33258 dye. Culture medium was removed and cells were 
washed with PBS. After washing, cells were harvested with Trypsin-EDTA (100 µl) 
and lysed with Millipore water (100 µl) followed by freeze-thaw-cycle. 200 µl of cell 
lyses buffer (20 mM Tris, 2 mM EDTA 5 mM NaCl, pH 7.4) containing 2 µg/ml 
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Hoechst 33258 dye were applied to each well, followed by another freeze-thaw-cycle. 
200 µl of cell suspension were transferred to a black bottom 96 well plate (Greiner-
Bio One, Frickenhausen, Germany). DNA content was determined by quantifying 
fluorescence signal using a SPECTRAFluor Plus plate reader (Tecan, Grödig, 
Austria), using excitation and emission filters centered at 360 nm (excitation) and 465 
nm (emission), respectively. 
2.1.6. TUNEL Assay 
Apoptotic cells were detected on paraffin embedded section of multicellular spheroids 
at different time points 24 h and up to 120 h after spheroids formation using a TUNEL 
assay (Roche, Penzberg, Germany) according to manufacturer instructions. Briefly: 
After dewaxing and rehydration according to standard protocols the spheroid 
sections were treated with proteinase K working solution (Roche, Penzberg, 
Germany) for 10 min. The TUNEL reaction mixture was added and incubated for 60 
min at 37°C in a humidified atmosphere. After intensive washing with PBS the 
sections were mounted with antifade and analyzed using a fluorescence microscope 
at 488 nm excitation (530 nm emission). 
2.1.7. Transfections 
2.1.7.1. Hsp27 siRNA transfection 
For siRNA applications, cells were seeded at a density of 6x 104 cells/well in 
antibiotic-free medium in 24-well plates and incubated at 37º C for 24 hours before 
transfection. Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) and siRNA (and 
nonfunctional mut-siRNA) were dissolved separately in Opti-MEM I (Invitrogen, 
Karlsruhe, Germany). After 5 min of equilibration at room temperature, each siRNA 
solution was combined with the respective volume of the Lipofectamine 2000 
solution, mixed gently, and allowed to form siRNA liposome complexes for 20 min at 
room temperature. The transfection mixture was added to the cells at a final 
concentration of 20-100 nM and 2 µl/mL Lipofectamine. Controls were treated with 
100 µl/ml Opti-MEM I, and vehicle controls with 2 µl/ml Lipofectamine 2000. The 
HSP27 siRNA sequence 5’-AAG-CUG-CAA-AAU-CCG-AUG-AGA-C-3 was reported 
to be effective in prostate cancer cells. Non functional control siRNA (mut-siRNA. 5’-
AUU-GUA-UGC-GAU-CGC-AGA-C-3’) was purchased from MWG Biotech 
(Ebersberg, Germany).  
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2.1.8. Immunocytochemistry  
2.1.8.1. Immunostaining of lamin A/C in multicellular spheroids  
After 4 d in culture multicellular spheroids were transferred to tissue freezing medium 
(Leica Microsystems, Nussloch, Germany) and frozen at -80°C. Cryosections (5 µm) 
were obtained with a Leica CM3050S cryostat (Leica Microsystems, Nussloch, 
Germany). Sections were transferred to microscope slides (SuperFrost, Menzel, 
Braunschweig, Germany), fixed in 4% paraformaldehyde, and subsequently treated 
with 0.2% Triton-X for 5 min. After blocking with 3% goat serum in PBS for 1 h the 
sections were incubated with rabbit anti-lamin A/C (1:100, cell signaling technology, 
Danvers, USA) or anti-cleaved lamin A antibody (1:100, cell signaling technology, 
Danvers, USA) in 3% goat serum in PBS at 4°C over night. Afterwards the sections 
were exposed to biotinylated goat anti-rabbit antibody (1:200, Vector Laboratories, 
Burlingame, USA) in 3% goat serum in PBS for 2 h at RT followed by incubation with 
Oregon Green streptavidin (Invitrogen, Karlsruhe, Germany) for 40 min in PBS. For 
counterstaining of the nuclei the slides were incubated with DAPI (4',6-Diamidino-2-
phenylindole) at a concentration of 1 µg/ml in PBS for 15 min.  
2.1.8.2. Immunostaining of Ki67 in multicellular spheroids 
Immunostaining was performed by the avidin–biotin–peroxidase complex staining 
method according to standard protocols. Briefly, paraffin sections were dewaxed and 
rehydrated. Antigen retrieval was performed by heat induction incubating the sections 
in 0.1 M citrate buffer (pH 6.0) for 60 min in the microwave. Sections were incubated 
with the primary antibody for 60 minutes at room temperature in a moist chamber. 
The proliferation antigen Ki67 was detected with mab MIB-1 (0.8 µg/ml, IgG1, Dako, 
Germany). After washing in PBS sections were incubated with a biotinylated antibody 
diluted (1:4000) in PBS for 30 minutes. Slides were incubated with peroxidase 
conjugated streptavidin (MIB-1). Peroxidase reaction was developed in AEC for eight 
minutes at room temperature. The sections were counterstained and mounted. 
2.1.8.3. Immunostaining for FACS analysis 
Cells were harvested with trypsin/EDTA solution and washed 1x with PBS prior to 
immunostaining. Primary antibodies were diluted 1:200 in PBS containing 5% FCS 
and staining was performed by incubating the cell with the antibody dilutionfor 1h on 
ice followed by 2 x washing with PBS containing 5% PBS. The secondary antibody 
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was diluted 1:400 in PBS containing 5% FCS for 45 min followed by 1 x washing with 
PBS containing 5% FBS resuspension of the cells in 700-100 µl of PBS containing 
5% FBS. Cells were kept on ice until analysis. 
2.1.9. Flow cytometry and microscopy 
2.1.9.1. FACS analysis 
FACS analysis was performed using a CYAN LX High Performance Flow Cytometer 
(DakoCytomation, Copenhagen, Denmark). Before analysis 1 µl of DAPI solution 
(1mg/ml) was added and the cell suspension was passed trough a filter to prevent 
occlusion of the machine. Alexa 488 fluorescence was excited at 488nm and DAPI 
fluorescence at 360nm. The fluorescence emission was detected using 530/40 nm 
band pass filter for Alexa 488 and 450/40 nm for DAPI. To exclude cell debris and 
doublets, cells were appropriately gated by forward versus sideward scatter. At least 
20 000 gated events were collected. 
2.1.9.2. Transmission light and epifluorescence microscopy 
Transmission light microscopy of living cells growing as monolayer cultures or 
multicellular spheroids was performed using an Axiovert 200 microscope (Carl Zeiss, 
Jena, Germany) equipped with a infinity2-C3 digital camera (Lumenera, Ontario, 
Canada). Light was collected trough a 5 x 0.12 NA, 10 x 0.25 NA or 32 x 0.40 NA 
objectives (Carl Zeiss, Jena, Germany). Images were collected using phase contrast. 
Immunofluorescently stained cells were analyzed using an Axiovert 200 microscope 
(Carl Zeiss, Jena, Germany) equipped with a Zeiss Axiocam camera. Light was 
collected through a 10 x 0.25 NA, 20 x 0.3 NA or a 63 x 1.4 NA objective (Carl Zeiss, 
Jena, Germany). Fluorescence was excited using either a 470±20 nm band pass 
filter for Alexa 488. Emission was collected using a 540±25 nm band pass filter. 
Digital image recording and image analysis was performed with Axiovision software 
(Carl Zeiss, Jena, Germany) 
2.1.9.3. Confocal laser scanning microscopy 
Detection of Oregon Green indicating lamin A/C or fragmented lamin A was 
performed using a fluorescent confocal laser scanning microscope (LSM 510 Meta, 
Carl Zeiss, Jena, Germany) at 488 nm excitation (530 nm emission), and DAPI 
fluorescence was detected at 364 nm excitation (385 nm long-pass emission). Image 
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recording was performed with the LSM 5 software, version 3.0 (Carl Zeiss, Jena, 
Germany). 
2.2. Protein analysis 
2.2.1. Bradford Assay 
Protein concentration was determined using the Bradford protein assay (BIORAD, 
Munich, Germany) according to manufacturer’s instructions. Samples for 2D-DIGE 
analysis were diluted at least 1:2 as the assay only tolerates 6 M urea. Bovine serum 
albumin (BSA) was used for the protein standard curve and was therefore diluted in 
the appropriate lysis buffer (Promega lysis buffer for western blotting, DIGE urea lysis 
buffer for 2DE) 
2.2.2. Westernblot 
2.2.2.1. Antibodies 
In order to detect the protein targets of interest the following antibodies were used in 
the corresponding western blot analyses: rabbit monoclonal antibody detecting full 
length lamin A/C and cleaved lamin A (1:1000, cell signaling technology, Danvers, 
USA), goat polyclonal antibody detecting acidic calponin (1:500, Santa Cruz 
Biotechnology, Heidelberg, Germany), mouse monoclonal antibody detecting keratin 
18 (1:500, cell signaling technology, Danvers, USA), mouse monoclonal anti-α-
Tubulin antibody (1:5000; Santa Cruz Biotechnology, Heidelberg, Germany), rabbit 
polyclonal antibody detecting annexin A3 (1:1000, Abcam ,Cambrigde, UK), mouse 
monoclonal antibody detecting cathepsin B (1:1000, Calbiochem, Darmstadt, 
Germany), mouse monoclonal antibody detecting cytokeratin 19 (1:1000, Exbio, 
Praha, Czech Republic), goat polyclonal antibody detecting thioredoxin domain 
containing protein 5 (1:2000, Abcam, Cambrigde, UK). The corresponding secondary 
antibodies were used as following: goat anti-rabbit HRP-conjugated secondary 
antibody (1:5000; Vector Laboratories, Burlingame, USA) or a rabbit anti-mouse 
HRP-conjugated secondary antibody (1:5000; Vector Laboratories, Burlingame, 
USA).  
2.2.2.2. Blotting procedure 
After SDS-PAGE using the Protean MiniGel system (BioRAD, Munich, Germany) and 
transfer to a PVDF membrane (Macharey Nagel, Düren, Germany) using a Trans 
Materials and Methods 20
Blot SD semidry blotting machine (BioRAD, Munich, Germany) the blot was probed 
with the appropriate antibody binding the protein target of interes in Tris buffered 
saline containing 0.5 % Tween (TBST) and 5% non feat milk powder at 4°C over 
night. After washing with TBST and PBS membranes were exposed to the 
corresponding secondary antibody followed by chemiluminescence detection (ECL; 
Amersham Biosciences, Arlington Hights, IL). Equal protein loading was controlled by 
reprobing the membrane with an antibody detecting a house keeping protein like α-
Tubulin or GAPDH.  
2.2.2.3. Imaging and quantitative analysis  
X-ray films were scanned using an Image Scanner (GE Healthcare, Munich, 
Germany) and quantitative analysis of the protein bands was performed by 
densitometry using ImageJ (Sun MicroSystems GmbH, Heimstetten, Germany). The 
house keepers GAPDH and α-tubulin provided the basis for normalization. For 
western blot analysis of ex vivo tumor tissue, the fraction of mouse protein within 
each sample has been determined using an appropriate anti-MHC antibody. 
Therefore western blots from tumor tissue have been compared to different amounts 
of SCID mouse proteins (Figure 8). The content of mouse protein within the tumor 
samples was below 3% (data not shown). 
 
 
 
Figure 8: Western blot analysis of different amounts of SCID mouse protein probed with an 
appropriate MHC antibody detecting SCID mouse MHC I. 
2.2.3. 2D-DIGE electrophoresis and mass spectrometry 
2D-DIGE electrophoresis was performed as described in the following passage. A 
schematic view is presented in Figure 9. 
 
 
 
 
 
 
 
Figure 9: Schematic view of 2D-DIGE experimental setup. 
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2.2.3.1. Sample preparation 
Cells grown as monolayers were harvested with trypsin/EDTA, washed 2 x with PBS 
and transferred to an Eppendorf tube. Washing solution was quantitatively removed 
before adding 500 µl of DIGE sample buffer (7 M urea, 2 M thioruea, 30 mM Tris, 4 
% CHAPS). Cells were shock frozen in liquid nitrogen before storage at -80°C until 
further processing. All centrifugation steps were carried out at 500 g for 5 minutes. 
Cell lysates were homogenized by centrifugation at 17500 g in a Qiashredder 
Homogenizer (Qiagen, Hilden, Germany) for 2 minutes. After the following 
centrifugation at 17600 g for 30 minutes supernatants were transferred into fresh 
Eppendorf tubes and protein concentration was determined by Bradford assay as 
described earlier (see 2.2.1). Samples were stored at -80°C. 
2.2.3.2. Protein labeling with DIGE dye 
Labeling with DIGE dyes (GE healthcare Bio-Science, Amersham plc, UK) was 
performed according to manufacturer’s instructions. The internal pooled standard 
(IPS) was prepared from equal protein amounts of each biological sample and 
labeled with the Cy2 fluorophore. Three biological and two techniqual replicates were 
performed. For each gel 50 µg aliquots of Cy2-,Cy3-,Cy5-labeled samples were 
combined and diluted with an equal volume of sample buffer ( 8 M urea, 4 % CHAPS, 
2 % dithioerythritol DTE, 2 % PharmalyteTM pH 3-10). Whenever required, labeled 
samples were stored at -80°C.  
2.2.3.3. 2-DE 
For Isoelectric focusing (IEF), the 24 cm gel strips with a gradient of pH 4-7 
(ImmobilineTM Dry Strips, GE Healthcare Bio-Science, Amersham plc, UK) were 
used. Labeled samples were applied to the strips by in gel rehydration followed by 
focusing in an Ettan IPGphor Isoelectric Focusing System (GE Healthcare 
Biosciences, Uppsala, Sweden; focusing time: 90 000 Vhs). IEF gels were stored at -
80°C until further processing. Prior to SDS-PAGE, gel strips were equilibrated for 15 
min in 10 ml equilibration buffer (50 mM Tris-HCl pH 6.8, 6 M urea, 30 % glycerin , 2 
% SDS) containing 1 % DTE, followed by a second 15 min equilibration step in 10 ml 
equilibration buffer with 2.5 % iodacetamide and 200 µl saturated bromophenolblue 
solution. 
SDS-PAGE (overall gel size 24cm x 18 cm x 1mm) was performed using a 11% 
separation gel [1.5 M Tris-HCL pH 8.8, 11 % acrylamide/ bisacrylamide (37.5:1), 0.1 
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% SDS, 0.05 % APS, 0:05 % TEMED] using a Ettan Dalt Twelve System (GE 
Healthcare Bio-Science, Uppsala, Sweden). IEF strips were placed onto the second 
dimension SDS polyacrylamide gels and fixed with 0.5 % agarose in SDS running 
buffer (25 mM Tris, 192 mM glycine, 0.1 % SDS). Gels were run for 45 min at 2.5 W/ 
gel followed by 4 h at 18 W/ gel in SDS running buffer at 20°C. 
2.2.3.4. Imaging and quantitative analysis 
Gels were scanned with a Typhoon 9400 fluorescence scanning device (GE 
Healthcare Bioscience) using the parameters suggested by the manufacturer for 2D 
DIGE experiments. Image analysis was performed with DeCyderTM Differential 
Software version v6.5 (GE Healthcare BioScience). Parameters for the spot detection 
algorithm were optimized manually and “estimated number of spots” was set to 3200. 
Only proteins, where the average normalized signals of all spots were increased 
respectively decreased more than 1.6 fold were taken into account in order to keep 
the false discovery rate low. In order to obtain significant data, three biological and 
two technical replicates of each group (6 replicates in total) were used for 
quantification. 
2.2.3.5. Excision and tryptic in gel hydrolysis of 2-D gel spots 
2D Gels were CBB-stained overnight (50 % Methanol, 0.05 % CBB R-250, 10 % 
acetic acid) and de-stained for 8 h (5 % methanol, 7 % acetic acid). Spots of interest 
were excised manually and transferred into 96-well reaction plates (Intavis, Köln, 
Germany). Digests were performed using a Digest- Pro MS digest robot (Intavis, 
Köln, Germany) with the following protocol: (i) wash step with 60 µl 50 mM 
NH4HCO3, (ii) wash step with 90 µl 50 % Acetonitril (ACN), 25 mM NH4HCO3, (iii) 
20 min wash with 60 µl ACN, (iv) 20 min wash with 60 µl 50 mM NH4HCO3 (v) 20 
min wash with 60 µl ACN (vi) 15 min wash with 60 µl ACN (vii) addition of 90 ng 
porcine trypsin (Promega, Madison, WI, USA) in 15 µl 50 mM NH4HCO3 and 
incubation at 37°C for 6 h, (viii) addition of 15 µl 2.5 % formic acid , and (ix) collection 
of the supernatant in 96-well collection plates (Intavis, Köln ,Germany) 
2.2.3.6. MALDI target preparation and MALDI-TOF-TOF analysis 
MALDI target preparation was performed with a DigestPro MS robot (Intavis) using 
the following protocol: (i) wetting of ZipTip C-18 reversed phase tips (Millipore, MA, 
USA) with 20 µl 50 % ACN, 0.1 % trifluoroacetic acid (TFA); (ii) equilibration with 20 
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µl 0.1 % TFA; (iii) loading of the tryptic peptides; (iv) washing with 20 µl 0.1 % TFA, 
and (v) elution of peptides onto the MALDI target plate with 1-2 µl 8 ml/ml cinnamic 
acid solution, 65 % ACN , 0.1 % TFA. 
MS and MS/MS spectra were acquired with 2500 laser shots (ND:Yag laser, 355 nm, 
N2 collision in the MS/MS mode) on a 4800 MALDI-TOF-TOF mass spectrometer 
(Applied Biosystems, CA, USA). Peak lists for MS spetra were generated with the 
4000 Series Explorer software using minimum S/N of 10 within the window of 50 m/z 
and cluster area S/N of 50. The peak lists for MS/MS spetra were generated using 
minimum S/N of 2 within the window of 500 m/z and cluster area S/N of 10. The PMF 
data subset was searched with Mascot against the human IPI v348 database with the 
following parameters: (i) fixed modifications: carbamidomethyl (C), (ii) variable 
modifications: oxidation (M), (iii) cleavage enzyme: trypsin (*KR), (iv) max missed 
cleavage:1, (v) Peptide mass tolerance mono: 0.5 Da, and (vi) Fragment mass 
tolerance mono 0.5 Da. Only proteins with a protein score > 90 were taken into 
account and every spot was identified by at least 2 MS/MS Spectra with a ions score 
> 30.  
2.3. RNA analysis 
2.3.1. RNA-extraction and concentration measurement for RT-PCR 
For RNA extraction 5 million cells were lysed in 350 μL of lysate buffer containing 
SDS and β-mercaptoethanol (Merck, Darmstadt, Germany) according to the 
manufacturer’s protocol (NucleoSpin RNA II Kit; Macherey and Nagel, Düren, 
Germany). After elution from the spin columns the RNA samples were stored at -
80°C until further use. RNA concentrations were determined at a wavelength of 
260/280 nm using a Biophotometer (Eppendorf, Hamburg, Germany). 
2.3.2. RT-PCR 
2.3.2.1. Primers 
Thymidylate synthase: forward, 5’-ATC-AAG-GGA-TCC-ACA-AAT-GC-3’and reverse, 
5’-GGT-CAA-CTC-CCT-GTC-CTG-AA-3’ 
Hsp27: forward, 5’-TTT-CTG-AGC-AGA-CGT-CCA-GA-3’ and reverse, 5’-CTT-TAC-
TTG-GCG-GCA-GTC-TC-3’ 
Materials and Methods 24
Glyceraldehyde-3-phosphatedehydrogenase (GAPDH): forward, 5’-CGT CTT 
CACCAC CAT GGA GAA GGC-3’ and reverse, 5’-AAG GCC ATG CCA GTG AGC 
TTC CC-3’ 
2.3.2.2. Procedure 
Reverse transcription (RT) was performed using M-MLV-reverse transcriptase 
(Promega, Mannheim, Germany) and oligo-dT-primers (MWG Biotech, Ederberg, 
Germany) to generate cDNA from 5 µg total RNA. The primers for Hsp27 and 
thymidylate synthase (TS) were used as described under 3.2.1. As a control, cDNA 
of the housekeeping gene glyceraldehyde-3-phosphatedehydrogenase (GAPDH) 
was amplified. The resulting specific PCR products had a length of 865 base pairs 
(bp) (HSP27), 205 bp (TS) and 400 bp (GAPDH), respectively. In a PX2 Thermal 
Cycler (Thermo electron corporation, Karlsruhe, Germany) the PCR was initiated with 
denaturation at 95°C for 2 min followed by addition of 5µl Thermoprime Plus 
polymerase 0.2 U/µl (Abgene, Hamburg, Germany) and 25-32 cycles (Hsp27), 26 
cycles (TS) and 23 cycles (GAPDH) of 30 s 95°C, 1 min 48°C (HSP27), 50°C (TS) or 
57°C (GAPDH), and 2 min 70°C, and final extension at 70°C for 10 min. PCR 
products were detected by ethidium bromide staining after 1.5% agarose gel 
electrophoresis and documented in a UV chamber (Raytest, Straubehardt, Germany) 
equipped with a CCD Camera (Raytest, Straubehardt, Germany). 
2.3.3. Micro Array Analysis 
Tumors were isolated and dissected as described in 2.4.6.2. The conserved tumor 
pieces were transferred to the laboratory of Dr. Helmut Blum where the RNA isolation 
and micro array analysis was performed according to the following protocol (Figure 
10).  
 
 
 
 
 
 
 
 
Figure 10: Schematic view of microarray analysis of RNA derived from PC3 xenografts in SCID mice. 
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2.3.3.1. RNA Isolation 
Trizol/chlorophorm extraction 
Tumor pieces were weighed and transferred to 2ml reaction tubes, shock frozen in 
liquid nitrogen and stored at -80°C for further processing. Frozen samples were 
homogenised in 1ml Trizol using a tissue homogenizer (Heidolph, Schwabach, 
Germany) and vortexed for 5 min. After each sample the homogenizer was cleaned 
by washing with 0.5N NaOH and RNAsefree water. In a second step phase 
separation was induced by adding 0.2 ml chlorophorm to each sample followed by 
the transfer of the aqueous phase containing the RNA into a new tube. After adding 
0.5 ml isopropanol the RNA was precipitated by centrifugation at 12 000g, 4°C for 45 
min. The pelleted RNA was washed two times with 75% EtOH followed each time by 
centrifugation (12 000g) for 10 min at 4°. After the second washing step the EtOH 
was removed and the pellet was dried at the unshielded flame. The dried pellet was 
dissolved in 53 µl RNAsefree H2O, first incubated with casual vortexing for 20 min at 
RT than at 42 °C on the thermomixer for 15 min. After that samples were put on ice, 
vortexed and spun down. 1.5 µl RNA-solution were used to determine the 
concentration at the nanodrop ND-100 (NanoDrop Technologies LLC, Wilmington, 
DE, USA). The RNA quality was tested on a 1% agarose gel. 
 
Ammonium acetate (NH4Ac) precipitation 
The samples were incubated with equal amounts (50µl) of a 5M NH4Ac solution and 
incubated for 30 min on ice followed by 45 min centrifugation at 25 000g (4°C). 
Thereafter the supernatant was removed and 250µl of a 2.5 M NH4Ac solution was 
added followed by 10 min centrifugation at 25 000g (4°C). After removal of the 
supernatant the pellet was resuspended in 500µl 75% EtOH previous to 
centrifugation for 5 min at 25 000g (4°C) and removal of 450µl of the supernatant. 
Storage of the samples at this stage at -20°C is possible. For further processing the 
supernatant was discarded completely and the pellet was dried at the unshielded 
flame before dissolving it in 102µl RNAsefree H2O for 15 min at 30°C in the 
thermomixer. Further on the concentration was monitored again using the nanodrop 
and RNA quality was tested by 1% agarose gel electrophoresis followed by EtBr 
staining of RNA.  
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Natrium acetate (NaAc) precipitation of the RNA 
For long-term storage an equal volume of isopropanol and 1/10th volume of NaAc 
were added to each sample, followed by shaking and spinning down previous to 
storage at -20°C. 
2.3.3.2. Control cDNA Synthesis 
The precipitated samples were thawed for 15 min at RT previous to 30 min 
centrifugation at 25000 g (18°C). Subsequently the supernatant was removed and 
stored until the concentration was measured at the nanodrop. Before measuring the 
concentration the pellet was washed with 500 µl 75% EtOH, centrifuged for 10 min at 
25 000 g (18°C) and dried at the unshielded flame. For concentration measurement 
the pellet was solved in 100 µl RNAsefree H2O. Whenever the concentration is too 
low the precipitation could be repeated. The quality was analyzed again by agarose 
gel electrophoresis with 200 ng RNA/ sample. cDNA synthesis was performed using 
10 µg RNA per sample in the superscript III kit from invitrogen (Karlsruhe, Germany) 
following manufacturer’s instructions. Finally the remaining RNA was digested and 
the quality of the cDNA was monitored by agarose gel electrophoresis as described 
previously. 
2.3.3.3. cDNA synthesis and hybridization 
Prior to the cRNA synthesis the concentration and quality of the RNA was again 
monitored as described earlier. The following steps including cDNA synthesis, cRNA 
synthesis, single strand cDNA synthesis and fragmentation of single strand cDNA for 
the Affymetrix human Gene Chip® Gene 1.0 ST array (Affymetrix, High Wycombe, 
UK) was carried out using the Affymetrix cDNA Synthesis & Amplification Kit 
according to the manufacturer’s instruction and all chemicals used were purchased 
from Affymetrix (High Wycombe, UK). Concentration and quality were monitored after 
each synthesis step following the procedure described previously. After each 
synthesis step the product can be shock frozen and stored at -80°C until further 
processing. After the enzymatic fragmentation of the single strand cDNA the 
fragments are labelled and final quality control before the hybridisation was 
performed on a 2% Biozym-Phor agarose gel using 300 ng cDNA of each sample. 
The hybridization cocktail was prepared and stored at -80°C until further use. Chips 
and samples were distributed equally into four groups for hybridization. The 
fragmented labelled cDNA was hybridized onto the human Gene Chip® HuGene 1.0 
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ST array in the hybridization furnace (Affymetrix, High Wycombe, UK). Staining and 
washing was performed in the fluidic station (Affymetrix, High Wycombe, UK) using 
the Affymetrix Gene Chip washing and stain kit (Affymetrix, High Wycombe, UK). 
Finally the chips were scanned on an affymetrix scanner using the CommandConsole 
software. 
2.3.3.4. Data analysis 
Quality control and normalization was performed R- based using the xps package 
from Bioconductor. Quality control data were visualized using arrayQualityMetrics 
1.8.1 under R 2.8.1. Statistical evaluation of the data was performed using the 
significance analysis of microarrays (SAM) (Tusher et al.2001) and the Spotfire 
Decision Site® from TIBCO (Munich, Germany) setting the false discovery rate to < 
5% and consider expression changes of >1.6-fold to be relevant. Genes have been 
clustered using the software “cluster” version 2.11 written by Michael Eisen84. 
2.4. Ex vivo/ in vivo experiments 
2.4.1. Animals 
Male SCID mice (CB17/lcr-PrkdcSCID/Crl) aged 8-10 weeks were housed in 
individually vented cages under specific pathogen free conditions with a 12h 
day/night cycle and with food and water ad libitum. 
2.4.2. Tumor models 
PC3 cells were cultured as described above. Cells were cultured without antibiotics 
for at least 3-4 passages, before tumor implementation and were harvested when 
reaching approx. 70% confluence. After washing with PBS 106 PC3 cells in 100µl 
PBS were injected subcutaneously with a 25G needle (Braun, Melsungen, Germany) 
into the flank of the mice.  
2.4.3. Tumor Measurement 
Animals were controlled regularly for tumor progression. When the tumor volume 
reached a size of at least 10mm3, tumor progression was monitored with a digital 
measuring slide (Digi-Met, Preisser, Gammertingen). Each measurement consisted 
of three diameters each 90° apart and tumor volume was calculated by the formula 
axbxcx0.4 (with a, b and c indicating the three diameters). 
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All animal procedures were approved and controlled by the local ethics committee 
and carried out according to the guidelines of the German law of protection of animal 
life. 
2.4.4. Chemotherapy 
The chemotherapeutical drug CPA (Cyclophosphamide, Sigma, Taufkirchen) was 
solved in PBS at a concentration of 10mg/ml followed by sterile filtration (0.22 µm 
sterile filter, Millex-GV, Millipore Carrigtwohill, Ireland). Application was performed 
intraperitoneally. The CPA solution was administered with a 25 G needle (Braun, 
Melsungen). The application of the CPA solution was carried out every 6th day. The 
single dose of each application was based on animal body weight. Toleration of the 
treatment with CPA was monitored by regular measurement of body weight. The 
vehicle group (PBS) and the drug treatment group (CPA dissolved in PBS) were 
housed separately.  
2.4.5. Tumor Histology 
2.4.5.1. HE stain 
Cryosections of the tissue was fixed with 4% paraformaldehyde and stained with 
Haematoxilin (Sigma, St. Loius, USA) for 30 min. After a washing step with PBS and 
aqua dest., sections were incubated with a 1:100 dilution of Eosin (Sigma, St. Louis, 
USA) for 4 min. Afterwards, sections were washed with aqua dest., embedded with 
PBS and analyzed by transmission light microscopy. Analysis was performed with an 
Anxiovert 200 microscope (Zeiss, Jena, Germany). 
2.4.5.2. Immunohistochemistry 
Cryosections (5µm) were transferred to a microscope slide and fixed with 4% 
paraformaldehyde (in PBS) for 5 min. Afterwards, tissue sections were rehydrated 
and washed with the blocking solution (PBS containing 5% FBS) prior to antibody 
incubation.  
Simultaneous staining for laminin and endothelial marker CD31: 
Staining was performed with the rabbit-anti-laminin antibody (Chemicon Europe, 
Hampshire, UK) and simultaneous with the rat-anti-mouse CD31 (CALTAG, 
Burlingame, USA) antibody; both antibodies were used in a 1:200 dilution (in the 
blocking solution). After an incubation time of 12h at 4ºC in a humidified atmosphere, 
sections were washed repeatedly with the blocking solution followed by secondary 
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antibody staining. Therefore the sections were incubated with the Texasred labelled 
goat-anti-rabbit antibody (Vector, Burlingame, UK) and the ALEXA488 labelled goat-
anti-rat antibody (Invitrogen, Oregon, USA); the staining was performed with a 1:200 
dilution (in blocking solution) of both antibodies for 2h at room temperature in a 
humidified atmosphere. Before analysis by fluorescence microscopy, sections were 
washed with the blocking solution repeatedly. Analysis was performed with a 
Anxiovert 200 microscope (Zeiss, Jena, Germany) using appropriate filter sets. 
2.4.6. Isolation of tumor/organs  
2.4.6.1. For Histology 
Tumors were dissected from the flank of sacrificed mice and embedded into cryo 
conservation medium (OCT tissue Tak, Sakura, USA) previous to freezing at -20°C , 
-80°C for long term storage. 
2.4.6.2. For Microarray analysis 
PC3-wt, PC3-A3, PC3-D3 and PC3-D4 were implanted subcutaneously and were 
grown as Xenografts for 10 days for the reisolated cells (PC3-A3, PC3-D3 and PC3-
wt) respectively for 17 days for the parental PC3-wt cells until they reached a mean 
volume of 35 mm³. At day 9 respectively 16 one group of each subline was treated 
with 120mg/kg CPA and the other group was used as untreated control. 24h after 
CPA application tumors were dissected from the flank of sacrificed mice and were 
divided into two parts. One half was embedded for histology as described in 2.4.6.1 
and the other half was cut into small pieces (Ø 0.5 mm). Randomly half of the pieces 
were collected and embedded in RNAlater (Ambion, Darmstadt, Germany) for RNA 
conservation. The rest of the pieces were prepared for FACS analysis as described 
in 2.3.3.  
2.4.7. Reisolation of tumor cells  
2.4.7.1. Isolation of tumor cells for cell culture 
For the reisolation of tumor cells, mice were sacrificed with CO2. The skin was 
cleaned and sanitized by isopropanol (70% in water v/v) followed by drying under 
sterile conditions. Tumors were collected and immediately inserted in the indicated 
Penstrep (Biochrome, Germany) containing RPMI medium. Tumor tissue was 
reduced to small pieces under sterile conditions. This procedure was repeated until 
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tumor tissue was homogenized. The obtained homogenized cell suspension was 
diluted with fresh medium, followed a centrifugation step (150g/5min). The 
supernatant was removed and the tumor cells were resuspended in fresh, Penstrep 
containing medium. The tumor cell containing suspension was transferred to collagen 
coated (Collagen G, Biochrom) tissue flasks (TPP, Switzerland) and incubated under 
standard conditions (37ºC, 5% CO2) in a humidified atmosphere for 2-3 days. When 
cells were attached to the bottom of the flasks, medium was replaced every second 
day, until cells reached a confluence of about 70%. Obtained cells were cultured for 2 
passages before harvested by tyrpsin/EDTA treatment. Reimplantation studies were 
performed by injection of 106 PC3 tumor cells at a passage number of 4-5.
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3.  Results 
3.1. Colon cancer 
3.1.1. Fragmentation of lamin A/C in multicellular spheroid cultures of low 
passage colon cancer cells 
3.1.1.1. Lamin A/C fragmentation in multicellular spheroids 
Previous proteomics data obtained from multicellular spheroid cultures compared to 
the corresponding monolayer cultures of low passage colon cancer cells revealed 
several differentially regulated protein candidates. In order to characterize these 
candidates in detail, western blot analysis and immunostaining was performed. 
Western blot analysis confirmed the down-regulation of acidic calponin in 3D cultures 
of COGA-5 and COGA-12 cells and revealed the presence of a lamin A/C fragment 
(approximately 30 kDa) in COGA-5 spheroids in addition to the intact lamins A and C 
(Figure 11 A, B).  
The focus of the present work was on the role of the lamin A fragment detected in 
multicellular spheroids by 2DE. Immunoblot analysis further revealed that the lamin 
A/C fragment was also detectable in partly compact COGA-12 aggregates (Figure 
11B). Notably, expression of lamin A/C and lamin A cleavage was less pronounced in 
COGA-12 aggregates compared to COGA-5 spheroids. 
 
 
 
 
 
 
 
 
Figure 11: (A) WB of acidic calponin in 2D and 3D cultures of COGA-5 and COGA-12 cells (B) lamin 
A/C expression in 2D and 3D cultures of COGA-5 and COGA-12 cells 
 
The fragmentation of lamin A was already present after 24 h in COGA-5 spheroids 
but increased in more compact spheroids, e.g. 96 h after spheroid formation (Figure 
12). 
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Figure 12: Time course of lamin fragmentation in 3D cultures of COGA-5 
 
TUNEL staining at different time points 24 h and up to 120 h after formation of 
COGA-5 spheroids revealed that the number of apoptotic cells also increased with 
time similar to the rising levels of fragmented lamin A in the COGA-5 spheroids 
(Figure 13). 
 
 
 
 
 
 
Figure 13: TUNEL stain of COGA-5 spheroids at different time points after spheroid formation  
3.1.1.2. Lamin A/C fragmentation in monolayer cultures after serum withdrawal 
Since COGA-5 spheroids were more compact and expressed more lamin A/C 
fragment compared to COGA-12 aggregates, we addressed the question whether the 
presence of truncated lamin A/C in spheroids could be associated with the lack of 
oxygen and/or trophic support, conditions known in compact areas of the spheroids85. 
Mimicking these conditions in monolayers western blot analysis revealed that the 
lamin A/C fragment was detectable in monolayer cells after serum withdrawal (Figure 
14). Hypoxia further enhanced the level of the protein fragment in cultures deprived 
of serum, whereas hypoxia alone was not sufficient to induce a lamin A fragmentation 
in cells cultured with medium containing 10% serum. The fragment was also detected 
in cells cultivated in medium with reduced serum concentration (2%) when 
simultaneously exposed to hypoxia (Figure 14). 
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Figure 14: Lamin A/C fragmentation after serum withdrawal and hypoxia 
3.1.1.3. Caspase mediated lamin A/C fragmentation 
It has been suggested that lamin A/C is cleaved in a caspase-dependent manner 
during apoptosis86.To confirm the involvement of activated caspases in the observed 
lamin A/C fragmentation in monolayer cultures, we applied the pan caspase inhibitor 
zVAD-fmk (10 and 50 µM) during serum deprivation. Caspase inhibition abolished 
the appearance of the lamin A/C fragment after serum deprivation in a dose-
dependent manner (Figure 15A). Further, the caspases 6-specific inhibitor zVEID-
fmk (50 µM) significantly attenuated the cleavage of lamin A/C (Figure 15B) in 
spheroid cultures of COGA-5 cells confirming that the observed lamin cleavage was 
mediated by caspase-6. 
 
 
 
 
 
 
Figure 15: Lamin A/C fragmentation is inhibited by (A) a pan caspases inhibitor (B) a caspases 6 
inhibitor. 
 
Western blot analysis using an antibody specific against caspase-cleaved lamin A 
fragment confirmed the previously observed lamin A/C fragment in monolayer cells 
challenged by serum withdrawal as a product of caspase cleavage (Figure 16). Such 
stress-induced caspase cleavage product was observed in cells deprived of serum in 
normoxia as well as in hypoxic conditions. 
no
rm
ox
ia
sp
he
ro
id
hy
po
xi
a
lamin A/C
α-tubulin
10 2 0 10 2 0 10 % FCS 
28kDa
70kDa
A 10 50
lamin A/C
α-tubulin
0
28kDa
70kDa
(µM) zVAD-fmk 0 50 (µM) zVEID-fmk
lamin A/C
α-tubulin
70kDa
28kDa
B
Results 34
 
 
 
 
 
 
 
Figure 16: Caspase 6 cleavage product of lamin A in serum-deprived monolayer cultures. COGA-5 
cells were incubated for 24 h at hypoxic and normoxic conditions and different amounts of growth 
factors. Lamin A/C fragment expression was analyzed by Western blot analysis using an antibody 
specific against the caspase cleavage product of lamin A. Results obtained in spheroid culture are 
given for comparison.  
 
In COGA-5 spheroids, immunocytochemistry revealed high levels of caspase-cleaved 
lamin A in individual cells that were distributed throughout spheroid without restriction 
to inner areas (Figure 17). It is important to note that in most cells positive for 
fragmented lamin A/C the nuclei appeared pyknotic or fragmented, indicating that 
enhanced lamin cleavage occurred in cells undergoing apoptotic cell death.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Distribution of lamin A/C and its caspase cleavage product within spheroids. Cryosections 
of COGA-5 spheroids were incubated with antibodies against full length lamin (A) and cleaved lamin 
(B) followed by a biotinylated antibody which was visualized by oregon green-streptavidin (green). The 
sections were analyzed by confocal microscopy. Control sections were only incubated with a 
biotinylated secondary antibody, counterstaining was performed with DAPI (blue). Arrows mark 
pyknotic nuclei from apoptotic, cleaved lamin positive cells. Photomicrographs representative for the 
whole spheroid are shown. (C) Overview of the distribution of lamin A/C and its caspase cleavage 
product within spheroids. Cryosections of COGA-5 spheroids were incubated with an antibody against 
full length lamin recognizing also the fragmented lamin of 28 kDa followed by a biotinylated antibody 
which was visualized by oregon green-streptavidin (green). The sections were analyzed by confocal 
microscopy. Sections of whole spheroids are shown. Control sections were only incubated with a 
biotinylated secondary antibody, counterstaining was performed with DAPI (blue). 
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Since we could observe caspases-6 dependent lamin A cleavage in multicellular 
spheroids, we further investigated if other caspases-6 substrates, e.g. cytokeratin 18 
(CK18), 9 were also cleaved during the apoptotic process in COGA-5 spheroids or 
COGA-12 aggregates. Western blot analysis revealed CK18 cleavage in both three 
dimensional cultures (Figure 18). Notably, induction of COGA cell apoptosis by 5-
fluorouracil (5-FU) or camptothecin was also accompanied by cleavage of lamin A 
and CK18, suggesting activation of similar caspase-dependent cell death pathways 
in COGA cells after spheroid formation, by deprivation of trophic support and 
hypoxia, or after exposure to chemotherapeutics. 
 
 
 
 
 
 
Figure 18: Expression of cytokeratin 18 (CK18) in 96 h old 3D cultures of COGA 5 and COGA 12 
compared to corresponding monolayer cultures and after 3 days treatment with chemotherapeutics 
such as camptothecin (25 µM) and 5-fluorouracil (5-FU) (20 µM). 
 
3.1.2.  5-FU chemoresistance in low passage colon cancer cells in vitro 
3.1.2.1. HSP27 expression in chemoresistant colon cancer cells 
The protein spot identified as Hsp27 on the 2D gel was detected only in 
chemosensitive COGA-12 cells and not in corresponding 5-FU resistant COGA-
12/G6 cells. In order to reveal if this protein regulation is due to decreased mRNA 
levels a semi-quantitative RT-PCR analysis was performed. It revealed lower levels 
of HSP27 mRNA in resistant COGA-12/G6 cells compared to 5-FU sensitive 
COGA12 (Figure 19A). Densitometry performed from three independent results 
confirmed significant HSP27 mRNA down regulation in COGA-12/G6 cells (Figure 
19B). 
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Figure 19: Hsp27 mRNA level in COGA-12 and COGA-12/G6 cells. (A)Gel-electrophoresis of RT-
PCR products using HSP27-primer and GAPDH-primer on COGA 12-cells and COGA-12/G6-cells 
respectively. (B) Grey value analysis of COGA12 and COGA-12/G6 cells from three independent 
experiments. 
 
Further validation of the 2DE data on protein level was performed by western blot 
analysis. Down-regulation of Hsp27 in 5-FU resistant COGA-12/G6 cells compared to 
corresponding parental COGA-12 cells could also be confirmed by western blot 
analysis. Hsp27 is down-regulated in COGA-12/G6 cells with and without CPA 
therapy whereas Hsp27 levels are higher in chemosensitive COGA-12 cells when 
treated with 5-FU (Figure 20). 
 
 
 
 
 
 
Figure 20: Westernblot analysis of Hsp27 in non resistant COGA-12 and chemoresistant COGA-
12/G6 cells under influence of 5-FU treatment 
 
In order to determine the functional relationship between the lower Hsp27 expression 
and the 5-FU resistance in COGA-12/G6 cells, Hsp27 was knocked down in 
chemosensitive COGA-12 cells by siRNA transfection. Therefore a Hsp27 specific 
siRNA sequence previously published by Rocchi et al. 2006 as well as a Dicer 
product established in our lab was used87. Hsp27 siRNA transfected cells were re-
seeded and treated with 5-FU 24 h after re-seeding. The knockdown of Hsp27 was 
controlled on mRNA level by RT-PCR 48 hours after transfection with Hsp27 siRNA. 
A clear knockdown could be detected in all COGA-12 cells transfected with Hsp27 
specific siRNA as well as with different concentrations of the Hsp27 Dicer product. 
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However, scrambled control siRNA did not induce any unspecific knockdown of 
Hsp27 in COGA-12 cells at the used concentration of 40nM (Figure 21). 
 
 
 
 
 
 
 
Figure 21: Hsp27 mRNA levels in COGA-12 cells 48 h after siRNA application. Gel-electrophoresis of 
RT-PCR products of Hsp27 mRNA from COGA12 cells transfected with HSP27 siRNA. Controls 
received Opti-MEM (-LF), lipofectamine 2000 (LF) or 40 nM non-functional siRNA. 
 
Cell viability was analyzed 72 h after 5-FU treatment by MTT-assay (Figure 22). 
HSP27 siRNA did not increase cell metabolic activity after 5-FU treatment compared 
to any of the controls. 
 
 
 
 
 
 
 
 
 
 
Figure 22: Cell viability of COGA12 transfected with X nM HSP27 siRNA was determined by the MTT 
assay 3 d after exposure to 5-FU. Controls received lipofectamine 2000 (LF) or 40 nM non-functional 
siRNA.  
3.1.2.2. Thymidylate synthase (TS) mRNA levels in chemoresistant colon 
cancer cells 
Up-regulation of mRNA levels of TS, the main target of 5-FU, is a classical resistance 
mechanism in 5-FU chemotherapy. As no functional relationship between down-
regulation of Hsp27 and 5-FU resistance in COGA-12/G6 cells could be detected, it 
was tested if any classical 5-FU resistance mechanism which was not obvious by 
2DE could be involved in resistance. Therefore the mRNA levels of TS were 
determined by RT-PCR and normalized to GAPDH levels in COGA-12 and COGA-
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12/G6 cells (Figure 23). Indeed, RT-PCR revealed higher mRNA levels of TS in 
COGA-12/G6 cells than in parental COGA-12 cells. 
 
 
 
 
 
 
Figure 23: mRNA levels of thymidylate synthase. Gel-electrophoresis of RT-PCR products of 
thymidylate synthase mRNA from COGA-12 and COGA-12/G6 cells. 
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3.2. Chemoresistance in metronomic cyclophosphamide therapy 
of prostate cancer xenografts: an in vivo chemoresistance  
3.2.1. Generation of an appropriate in vivo passaged control  
PC3-A3 cells have been reisolated from PC3-wt xenografts which have been grown 
in vivo without metronomic CPA treatment. Reisolation was performed as for the 
previously reisolated PC3-D3 and PC3-D4 cells (see 2.4.7.1) 
3.2.1.1. Morphology 
In order to control the identity of the reisolated in vivo passaged PC3-A3 cells their 
morphology after reisolation was examined by transmission light microscopy in 
comparison to corresponding PC3-wt cells. No major morphological changes 
compared to the PC3-wt cells could be observed in PC3-A3 cells (Figure 24).  
 
 
 
 
Figure 24: Morphologies of (A) PC3-wt and (B) reisolated in vivo passaged PC3 cells (PC3-A3).  
3.2.1.2. Receptor status 
As PC3-wt cells highly express the human EGF- receptor (EGFR) as well as the 
human transferrin receptor (CD71) human specific antibodies against these two 
receptors were used to prove the human origin of reisolated cells and their similarity 
to PC3-wt cells in terms of characteristic cell surface expression. Figure 25 displays 
that 99.9% of PC3-A3 cells show expression of hEGFR and 95.6% expression of 
human CD71 receptor which is similar to expression levels in PC3-wt and PC3-D3, 
PC3-D478. 
 
 
 
 
 
 
Figure 25: Receptor status for human EGF receptor and human CD71 on reisolated in vivo passaged 
PC3-A3 cells. 
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3.2.2. Drug efflux activity of reisolated PC3 cells 
To consider up-regulation of drug efflux pumps as possible resistance mechanisms, 
Hoechst dye efflux assay was performed. In none of the tested cell lines PC3-D3, 
PC3-D4 (resistant) and PC3-A3 (in vivo passaged) a distinctive side population, 
characterized by higher efflux of the Hoechst 33342, was detected. Co-treatment with 
Verapamil and Hoechst 33342 confirmed the absence of a Verapamil sensitive side 
population (Figure 26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Efflux pump activity was measured for PC3-A3 control cells and resistant variants PC3-D3 
and PC3-D4 by incubation with Hoechst 33342 dye in the presence of Verapamil (A, C and E) and in 
the absence of Verapamil (B, D F). A distinctive population with decreased fluorescent signal, 
indicating increased pump activity was not detectable for all tested PC3 cell lines. Furthermore, no 
differences in Hoechst dye uptake were detectable, when Hoechst dye 33342 incubation was 
performed in the presence of Verapamil compared to samples incubated in the absence of Verapamil. 
The study was performed in three biological and two technical replicates, respectively.  
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3.2.3. Proliferation of reisolated cells under hypoxic conditions 
5000 cells of each reisolated PC3 cell line (PC3-A3, PC3-D3 and PC3-D4) were 
seeded into 6-well plates and were cultivated up to seven days at either normoxic or 
hypoxic (0.1% O2) conditions. Proliferation was determined by measuring DNA 
content using Hoechst 33342 based proliferation assay. Under normoxia reisolated 
PC3 cells from resistant tumors (PC3-D3 and PC3-D4) did not show increased 
proliferation compared to in vivo passaged PC3-A3 cells. Also hypoxia did not reveal 
significantly increased proliferation within the resistant PC3 cells. However, PC3-D4 
cells showed a tendency of proliferation advantage after seven days of cultivation 
under hypoxic conditions (Figure 27) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Proliferation of reisolated PC3 cells under normoxic and hypoxic conditions. 
3.2.4. Reimplantation of reisolated PC3 cells 
3.2.4.1. Resistance of reimplanted PC3 (PC3-D3 and PC3-D4) towards 
metronomic CPA therapy in vivo 
Reisolated PC3 tumor cells PC3-D3 and PC3-D4 derived from tumors resistant 
towards metronomic CPA therapy in previous studies which did not manifest their 
resistance in vitro (Figure 7) were implanted in the flank of male SCID mice. On day 
10 after tumor implantation, when average tumor volume reached 28 mm3, mice were 
again subject to CPA treatment (120mg/kg, every six days). In contrast to achieved 
growth delay of parental tumors in the first CPA treatment and in the group with PC3-
wt cells (Figure 7B), in the case of reimplantated PC3-D3 and PC3-D4 tumors only a 
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weak growth retardation effect was detectable (Figure 28). Control tumors as well as 
treated D3 and D4 tumors showed an average tumor volume doubling time of 
approximately three days (Figure 28). Metronomic scheduled CPA was again well 
tolerated, indicated by no significant loss in body weight (data not shown).  
 
 
 
 
 
 
 
 
Figure 28: Tumor growth of reimplanted PC3 cancer cells. Resistant CPA treated tumors (PC3-D3 
and PC3-D4) were cultured in vitro and after several passages implanted again sc in male SCID mice. 
Mice were treated with 120mg/kg every sixth day. (n=5 for control and CPA treated animals). 
3.2.4.2. Chemosensitivity of reimplanted in vivo passaged PC3 cells (PC3-A3) 
In a control experiment 106 in vivo passaged control tumor cells (PC3-A3) and PC3-
wt cells were injected subcutaneously into the flank of SCID mice. Metronomic CPA 
therapy (120mg/ kg CPA every six days) was started at day 14 after tumor cell 
implantation. Despite an innate increased proliferation rate in vivo, PC3-A3 cells 
showed similar chemosensitivity towards metronomic CPA therapy as parental PC3 
cells (PC3-wt) for a treatment period of  42 days (Figure 29). 
 
 
 
 
 
 
 
 
 
 
Figure 29: Tumor growth of reimplanted in vivo passaged PC3 cancer cells. In vivo passaged CPA 
treated tumors (PC3-A3) were cultured in vitro and after several passages implanted again sc in male 
SCID mice.PC3-wt served as control. Mice were treated with 120mg/kg every sixth day. (n=5 for 
control and CPA treated animals). 
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3.2.5. Expression of vascular markers and functionality of tumor blood flow in 
reimplanted tumors 
To determine the angiogenic potential of the different reimplanted cell lines PC3-D3, 
PC3-D4 (resistant) and PC3-A3 (in vivo passaged) and to follow possible 
antiangiogenic effects of the treatment, quantification of functional tumor blood flow 
was again determined by using Hoechst dye as a tracer. The initial functional blood 
flow in the resistant tumors, compared to PC3-A3 did not show any significant 
differences. The treatment regimen (120mg/kg, every six days) resulted in slightly 
reduced blood supply for PC3-A3 and the resistant tumors in a similar extent. 
However, after two cycles of CPA application, blood flow reduction was statistically 
significant neither in resistant tumors nor in PC3-A3 in comparison to the initial blood 
flow in untreated animals. 
Vasculogenic mimicry was already described in prostate cancer and prostate cancer 
xenografts and would be a possible escape mechanism from antiangiogenic 
treatment approaches47. Therefore, reimplanted resistant PC3-D3 and PC3-D4 were 
analyzed for vascular markers in combination with functional blood flow using 
Hoechst 33258 as a tracer. Analysis was performed before and after two applications 
of CPA. Vasculogenic mimicry was neither detectable in untreated tumors PC3-D3 
and PC3-D4 nor under therapeutic pressure. All functional blood channels within the 
tumors, indicated by Hoechst fluorescence, were detected to be associated with 
vascular markers by the host (Figure 30). Co-staining of murine and human laminin 
in combination with staining for murine endothelial cells and functional blood flow 
confirmed the absence of functional laminin containing structures without 
participation of murine endothelial cells (Figure 30). 
Results 44
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Reimplanted control tumors PC3-A3 and resistant variants PC3-D3 and PC3-D4 were 
analyzed after a 14 day treatment for functional blood flow (A). Hoechst dye 33258 was used as a 
tracer. Quantified fluorescence signal in tumors obtained from untreated control animals are 
represented by filled symbols. Quantified Hoechst fluorescence in tumors obtained from treated 
animals are represented by open symbols. Twelve sections per tumor were examined and three areas 
per section were randomly selected for image analysis. Cryosections (5 µm) of reimplanted, untreated 
PC3-D3 (B-1) and PC3-D4 (B-3) and CPA treated tumors PC3-D3 (B-2) and PC3-D4 (B-4) were fixed 
with 4 % PFA and stained with an antibody detecting human and murine laminin (orange) and murine 
CD31 (green). Functional blood flow was visualized by intravenous application of Hoechst 33258 dye 
(blue). No functional blood flow was detected in areas without murine CD31 staining. For analysis, 
antibody staining was performed for two tumors of each group. 
3.2.6. 2D-DIGE analysis of reisolated in vivo resistant PC3-D3 and PC3-D4 
cells versus PC3-wt cells 
3.2.6.1. Different protein expression pattern in resistant versus wt PC3 cultures 
PC3-wt, PC3-D3 and PC3-D4 were grown in standard monolayer cultures, and cell 
extracts of both reisolated PC3 cell lines (PC3-D3 and PC3-D4) and the parental 
PC3-wt cell line were subject to 2D-DIGE (Figure 31). Proteome analysis revealed 
different expression of seven protein spots in PC3-D3 cells compared to the PC3-wt 
(four up- and three down-regulated) (Figure 31A) and altered expression of 18 
protein spots in PC3-D4 compared to PC3-wt (nine up- and nine down-regulated) 
(Figure 31B). Only proteins, where the average normalized signals of all spots were 
increased respectively decreased more than 1.6 fold were taken into account. Three 
spots were up-regulated (D3-1/D4-2, D3-3/D4-1, D3-4/ D4-5), one spot (D3-5/D4-14) 
down-regulated in both reisolated cell lines. The other spots were regulated only in 
either the PC3-D3 or the PC3-D4 compared to the PC3-wt (Figure 31C).  
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Figure 31: Differences in the expression profiles of resistant and their corresponding wildtype PC3 
cells obtained by 2D-DIGE. 2D-DIGE of cell lysates of the cell lines PC3-wt and PC3 resistant were 
performed with IPG dry strips pH 4 - 7 in the first dimension and 11 % SDS-polyacrylamid gels in the 
second dimension. Representative DIGE-gels of protein regulations (A) between PC3-D3 and PC3-wt 
and (B) between PC3-D4 and Pc3-wt are shown. (C) Overlap of the differentially expressed protein 
spots between PC3-D3 and PC3-D4. 
3.2.6.2.  Protein expression differences in PC3 cells due to in vivo passaging 
In order to differentiate between protein regulations caused by in vivo passaging of 
the reisolated tumor cells the appropriate in vivo passaged control cells PC3-A3 have 
also been compared to the PC3-wt cells (Figure 32). This control experiment 
revealed eight differentially expressed protein spots between PC3-A3 and PC3-wt 
(two up-regulated and six down-regulated in PC3-A3). 
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Figure 32: (A) Differences in expression profiles of in vivo passaged PC3-A3 cells and their 
corresponding wildtype PC3 cells obtained by 2D-DIGE. 2D-DIGE of cell lysates of the cell lines PC3-
wt and PC3-A3 were performed with IPG dry strips pH 4-7 in the first dimension and 11% SDS-
polyacrylamid gels in the second dimension. Representative DIGE-gels of protein regulations between 
PC3-A3 and PC3-wt are shown. (B) Overlap of the differentially expressed protein spots between 
PC3-A3 and PC3-D4. 
 
Three spots A-1/D4-3, A-3/D4-12 and A-4/D4-10 showed similar regulations in PC3-
A3 and PC3-D4 and also low non significant regulation in PC3-D3 compared to the 
PC3-wt (Figure 32B) but none of the four spots detected in both resistant PC3 cell 
lines could be detected as differentially expressed in PC3-A3 compared to the 
corresponding PC3-wt. 
3.2.6.3. Mass spectrometry-based identification of differentially expressed 
proteins  
Excised spots were trypsinized and analyzed by MALDI-PMF as well as MS/MS 
using MALDI-TOF-TOF or LC-MS/MS. MALDI-PMF data as well as MS/MS data 
were searched with Mascot search against the human IPI v348 database. As 
minimum criterion for successful identification Mowse protein score > 90 was chosen 
for PMF data, and in case of MS/MS analysis the presence of at least two spectra 
with ion score > 30 was mandatory: Using these criteria we succeeded in the 
identification of 25 spots. The results of the MALDI-MS spot identification are 
summarized in Table 3 for the resistant cell line PC3-D3 compared to PC3-wt, in 
Table 4 for the resistant cell line PC3-D4 compared to PC3-wt and in Table 5 for 
PC3-A3 compared to PC3-wt cells. 
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spot 
no. 
identified 
protein 
Database accession 
no. 
T-test Av. 
Ratio 
theoretical 
MW (kDa) 
exp. 
MW 
(kDa)
theoretical 
pI 
exp. 
pI 
protein 
score 
sequence 
coverage 
% 
no. of 
matched 
peaks 
D3-1 Annexin A3 IPI human IPI00024095 0.00032 1.82 36 30-40 5.6 5.7 920 68 33 
D3-2 Programmed 
cell death 
protein 6 
(ALG-2) 
IPI human IPI00025277 1.80E-05 1.75 21 15-20 5.1 4.9 354 46 16 
D3-3 Keratin, 
Type I 
cytoskeletal 
19 
IPI human IPI00479145 4.90E-05 1.75 44 40-45 5.0 5.0 1020 84 48 
D3-4 cathepsin B 
precursor 
IPI human IPI00295741 2.70E-07 1.69 38 20-25 5.8 5.2 194 29 19 
D3-5 thioredoxin 
domain 5 
isoform 2 
IPI human IPI00395646 8.70E-06 -1.63 44 50-60 5.7 5.50 229 57 23 
D3-6 similar to 
protein 
phosphatase 
1 regulartory 
subunit 14B 
IPI human IPI00398922 1.10E-06 -1.77 21 15-20 5.1 4.80 91 12 2 
D3-7 Isoform 
SNAP 23a of 
synaptosom
al-
associated 
protein 23 
IPI human IPI00010438 3.00E-06 -1.78 23 20-25 4.9 4.80 311 62 19 
 
Table 3:. Differentially expressed proteins in PC3-D3 vs PC3-wt identified by MALDI TOF TOF MS 
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spot 
no. identified protein Database 
accession 
no. T-test 
Av. 
Ratio 
theor. 
MW 
(kDa) 
exp. 
MW 
(kDa) 
theor. 
 pI 
exp. 
pI 
protein 
score 
sequence 
coverage 
% 
no. of 
matched 
peaks 
D4-1 Keratin, Type I cytoskeletal 19 IPI human IPI00479145 8.70E-08 2.16 44 40-45 5.0 5.0 882 69 41 
D4-2 Annexin A3 IPI human IPI00024095 9.80E-06 2.15 36.5 30-40 5.6 5.7 703 57 30 
D4-3 Keratin, Typ II cytoskeletal 8 IPI human IPI00554648 1.70E-06 1.90 54 40-50 5.5 5.6 741 59 45 
D4-4 Leupaxin IPI human IPI00299066 9.60E-06 1.77 45 40-50 5.6 5.8 259 38 18 
D4-5 Cathepsin B  IPI human IPI00295741 2.70E-06 1.75 38 20-25 5.8 5.2 400 23 14 
D4-6  Cathepsin B IPI human IPI00295741 8.60E-06 1.75 38 25-35 5.8 5.3 364 36 18 
D4-7  Cathepsin B IPI human IPI00295741 4.50E-06 1.73 38 20-25 5.8 5.2 199 20 13 
D4-8 
Isoform 3 of UDP-N-
acetylhexosamine 
pyrophosphorylase 
IPI human IPI00607787 2.10E-05 1.72 59 55-65 5.9 6.2 427 49 29 
D4-9 Keratin, Type I cytoskeletal 18 IPI human IPI00554788 2.20E-06 1.64 48 40-50 5.3 5.5 765 72 47 
D4-10 
HSPD1 60 kDa heat 
shock protein, 
mitochondrial 
IPI human IPI00784154 1.10E-08 -1.68 61 50-60 5.7 5.3 949 56 36 
D4-11 Protein NDRG1 IPI human IPI00022078 3.00E-06 -1.70 43 40-50 5.5 5.7 254 40 24 
D4-12 
HSPD1 60 kDa heat 
shock protein, 
mitochondrial 
IPI human IPI00784154  6.70E-09 -1.74 61 50-60 5.7 5.3 1100 67 49 
D4-13 
Thioredoxin domain-
containing protein 5 
precursor 
IPI human IPI00171438  4.10E-07 -1.80 44 40-45 5.8 5.4 616 61 29 
D4-14 
Thioredoxin domain-
containing protein 5 
precursor 
IPI human IPI00171438  1.20E-06 -1.84 44 40-45 5.8 5.5 240 18 7 
D4-15 
Pyruvate 
dehydrogenase E1 
component subunit 
alpha, somatic form, 
mito (PDHA1) 
IPI human IPI00902645 2.70E-06 -1.93 44 45-50 8.3 6.2 409 50 23 
D4-16 Latexin  IPI human IPI00106687 4.60E-06 -2.29 26 25-30 5.5 5.7 108 13 2 
D4-17 Protein NDRG1 IPI human IPI00022078 6.20E-06 -2.45 43 40-50 5.5 5.6 235 15 6 
D4-18 Protein NDRG1 IPI human IPI00022078 1.10E-06 -2.47 43 40-50 5.5 5.7 371 25 9 
 
Table 4:. Differentially expressed proteins in PC3-D4 vs PC3-wt identified by MALDI TOF TOF MS 
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spot 
no. 
identified 
protein Database 
accession 
no. T-test 
Av. 
 Ratio 
theor. MW 
(kDa) 
exp. 
MW 
(kDa) 
theor. 
pI 
exp. 
pI 
protein 
score 
sequence 
coverage 
% 
no. of 
matched 
peaks 
A3-1 
KRT8 Keratin, 
type II 
cytoskeletal 8 
IPI human IPI00554648 0.00019 -1.77 54 50-60 5.5 5.9 265 26 19 
A3-2 
HSPD1 60 
kDa heat 
shock protein, 
mitochondrial 
IPI human IPI00784154 1.00E-04 -1.74 61 50-60 5.7 5.5 184 11 10 
A3-3 
HSPD1 60 
kDa heat 
shock protein, 
mitochondrial 
IPI human IPI00784154 3.00E-03 -1.69 61 50-60 5.7 5.4 888 35 30 
A3-4 
HSPD1 60 
kDa heat 
shock protein, 
mitochondrial 
IPI human IPI00784154  0.00051 -1.67 61 50-60 5.7 5.4 5521 64 221 
A3-5 
HSPA9 
Stress-70 
protein, 
mitochondrial 
IPI human IPI00007765 1.40E-02 -1.63 74 70-80 5.9 5.2 203 19 22 
A3-6 
P4HB Protein 
disulfide-
isomerase 
IPI human IPI00010796 0.017 -1.62 58 50-60 4.8 5.7 108 10 10 
A3-7 
HCLS1 
Hematopoietic 
lineage cell-
specific 
protein* 
IPI human IPI00026156  0.0033 1.81 54 70-80 4.7 4.8 534 22 16 
A3-8 
ARHGDIA 
Rho GDP-
dissociation 
inhibitor 1* 
IPI human IPI00003815  1.20E-02 2.62 23 20-30 5.0 5.0 341 32 14 
 
Table 5:. Differentially expressed proteins in PC3-A3 vs PC3-wt identified by MALDI TOF TOF MS 
and LC-MS/MS. * Measured by LC MS/MS. 
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3.2.7. Validation of potential protein candidates 
In order to validate the data obtained by 2DE several protein candidates were 
analyzed by western blotting in vitro and in vivo. For further validation, the four 
protein candidates similarly regulated in both resistant PC3 sublines were chosen. 
 
3.2.7.1. CK19: the importance of validation of proteomics data 
CK19 expression in vitro 
Cytokeratin 19 (CK19), a protein previously associated with chemoresistance in 
MCF-7 breast cancer cells88 was found to be up-regulated in PC3-D3 (1.8-fold) and 
PC3-D4 cells (2.2-fold) compared to corresponding PC3-wt cells by 2D-DIGE. 
However up-regulation could not be confirmed by western blot analysis of the 
corresponding protein extracts (Figure 33). 
 
 
 
 
 
 
 
Figure 33: Western blot analysis of CK19 expression in PC3 monolayer cultures in vitro.  
 
CK19 expression in vivo 
The up-regulation of CK19 in both resistant PC3 sublines detected by 2D-DIGE could 
not be confirmed in cell extracts from in vivo tumor tissue. Furthermore, CPA 
treatment did not show a consistent influence on CK19 levels in PC3-D3 and PC3-D4 
cells. 
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Figure 34: In vivo validation of CK19 regulation. Western blot analyses for CK19 of cell extracts from 
tumor tissue of resistant PC3-D3 and PC3-D4 tumors with and without metronomic cyclophosphamide 
treatment compared to tumors of PC3-wt with and without treatment. (B) Densitometric quantification 
of western blot analysis of CK19 from tumor tissue (n=4)  
3.2.7.2. Mitochondrial localization of truncated Cathepsin B in chemoresistant 
PC3 cells 
Spot D3-4 and D4-5 both of approximately 22 kDa with an isoelectric point (pI) of 5.2 
represent cathepsin B, up-regulated in both resistant cell lines. In PC3-D4 cells there 
are two more spots with a molecular weight of 23 kDa (D4-6) and approximately 
32kDa (D4-7) identified as cathepsin B (CatB). Western blot analysis of the 
corresponding protein extracts confirmed an upregulation of three cleavage products 
of cathepsin B in the resistant sublines (especially the PC3-D4) compared to the 
corresponding PC3-wt cells (Figure 35). 
 
 
 
 
 
Figure 35: Western blot analysis of Cathepsin B expression in PC3 monolayer cultures in vitro.  
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Furthermore, western blots of isolated mitochondria from PC3-wt, PC3-D3 and PC3-
D4 for CatB showed that the 32 kDa protein and a truncated version of the indicated 
protein (approximately 23 kDa) were localized to the mitochondria in the resistant 
sublines in contrast to the PC3-wt where it is located in the cytoplasm (Figure 36). 
 
 
 
 
 
Figure 36: Western blots of isolated mitochondria from PC3-wt, PC3-D3 and PC3-D4 for cathepsin B 
showed that the 32 kDa protein and a truncated version of the indicated protein (approximately 23 
kDa) localizes to the mitochondria in the resistant sublines. 
 
The upregulation of the active form of CatB (32 kDa) and its truncated versions (22 
kDa, 23 kDa) in the resistant PC3-D3 and/or PC3-D4 cells which was detected in the 
2D-DIGE experiment and western blotting from PC3 monolayer cultures could not be 
confirmed by western blotting from cell extracts of the corresponding in vivo tumor 
material (Figure 37).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37A: In vivo validation of CatB regulation. Western blot analyses for CatB of cell extracts from 
tumor tissue of resistant PC3-D3 and PC3-D4 tumors with and without metronomic cyclophosphamide 
treatment compared to tumors of PC3-wt with and without treatment. 
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Figure 37B: Densitometric quantification of western blot analysisof protein extracts derived from tumor 
tissue. (B) quantification of the westernblot protein band of active cathepsin (32 kDa). (C) 
Quantification of the western blot protein band detecting truncated cathepsin B (23k Da) 
3.2.7.3. CPA inducible expression of TXNDC5 in chemoresistant PC3 cells 
Low levels of TXNDC5 in vitro  
Another protein changed in abundance in both resistant sublines was identified as 
thioredoxin domain containing protein 5 (TXNDC5). This protein was detected to be 
decreased in PC3-D3 by the factor of 1.6 (spot D3-5) and in PC3-D4 by the factor of 
1.8 (spot D4-13 and D4-14) compared to the respective PC3-wt cells. Western blot 
analysis of the protein extracts in vitro confirmed these results (Figure 38).  
TXNDC5 expression under hypoxia  
Cultivation of reisolated PC3 cells under hypoxic conditions show reduction of 
TXNDC5 levels in all reisolated cells including the in vivo passaged PC3-A3 cells. 
This did not correlate with data obtained by 2D-DIGE where down-regulation had 
been specifically detected in resistant PC3 cells (PC3-D3 and PC3-D4) (Figure 38).  
 
 
 
 
 
 
 
 
 
 
Figure 38: (A) Western blot analysis of TXNDC5 expression in PC3 monolayer cultures in vitro under 
normoxic versus hypoxic conditions. (B) Densitometric quantification of western blot analysis (n≥4) 
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Selective induction of TXNDC5 under metronomic CPA therapy in vivo 
Western blot analysis of corresponding tumor tissue from PC3 xenografts confirmed 
the significant lower levels of TXNDC5 in PC3-D3 and a trend for lower expression of 
TXNDC5 in PC3-D4 in vivo (Figure 39). Metronomic scheduled CPA therapy in vivo 
increased protein levels of TXNDC5 in the resistant tumors but not in the PC3-wt 
(Figure 39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: In vivo validation of TXNDC5 regulation. Western blot analyses for TXNDC5 of cell extracts 
from tumor tissue of resistant PC3-D3 and PC3-D4 tumors with and without metronomic 
cyclophosphamide treatment compared to tumors of PC3-wt with and without treatment.  
3.2.7.4. ANXA3 is up-regulated in prostate cancer chemoresistance in vivo 
ANXA3 expression in vitro  
The 2D-DIGE analysis of in vitro cultures of the chemoresistant PC3-D3 and PC3-D4 
cells revealed a 1.8-fold increase of annexin A3 (ANXA3) in the PC3-D3 cells and a 
2.2-fold increase in PC3-D4 cells compared to the chemosensitive PC3-wt cell line. In 
order to validate these results, protein extracts from different PC3 sublines were 
analyzed by western blot analysis for the regulation of ANXA3 in vitro. Protein levels 
were normalized to the house keeping protein α-tubulin and levels were quantified by 
gray value analysis after the blots were scanned. Western blot analysis also detected 
an increase in ANXA3 expression in the resistant PC3 cells even if the protein levels 
in PC3-D4 were only slightly higher than in the PC3-wt cells (Figure 40). 
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Figure 40: Western blot analysis of ANXA3 expression in PC3 monolayer cultures in vitro.  
ANXA3 is induced in response to hypoxia 
Cultivation of reisolated PC3 cells for the duration of four days under hypoxic 
conditions in comparison to normoxic conditions revealed that ANXA3 is up-regulated 
by hypoxia in all three cell lines independently of their origin from resistant or non 
resistant tumors (Figure 41). 
 
 
 
 
 
 
 
 
Figure 41: Western blot analysis of ANXA3 expression in (A) PC3-D3 and (B) PC3-D4 compared to 
PC3-A3 monolayer cultures in vitro under normoxic versus conditions.  
 
ANXA3 up-regulation by resistant tumors in metronomic chemotherapy in vivo 
In order to reveal relevance of obtained in vitro data for in vivo chemoresistance, 
western blot analysis on tumor cell extracts of corresponding xenografts was 
performed (Figure 42). These western blots confirmed an up-regulation of ANXA3 in 
resistant tumors compared to chemosensitive control tumors. Importantly, the 
abundance of this protein further increased when tumor-bearing mice were subjected 
to CPA treatment. 
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Figure 42: In vivo validation of ANXA3 regulation. Western blot analyses for annexin A3 of cell 
extracts from tumor tissue of resistant PC3-D3 and PC3-D4 tumors with and without metronomic 
cyclophosphamide treatment compared to tumors of PC3-wt with and without treatment.  
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3.2.8. Microarray analysis of chemoresistant PC3 xenografts compared to non 
resistant control tumors 
In addition to the proteomics study a microarray analysis was performed to obtain 
additional information on mRNA level. Microarray was carried out on tumor tissue 
RNA. Therefore, PC3-wt, PC3-A3, PC3-D3 and PC3-D4 cells were injected 
subcutaneously and were grown as xenografts until they reached a mean volume of 
30 mm³. One group of each PC3 cell line was treated with 120mg/kg CPA, whereas 
the other group was used as untreated control. 24 h after CPA application tumors 
were harvested. Microarray analysis of 4 tumors per group using human Gene Chip® 
gene 1.0 ST array was performed.  
3.2.8.1. Sample classification via hierarchical clustering 
Robust Multichip Analysis (RMA) can be used to generate normalized expression 
intensities for a set of Affymetrix GeneChip files. In order to detect distances and 
similarities between different samples, RMA normalized data were subject to 
hierarchical clustering analysis. Hierarchical sample clustering compares the different 
samples to each other in terms of sample to sample variation in total gene 
expression89. The resulting distance matrix was visualized as so called heatmap, 
where samples which correlate well to each other in terms of their whole gene 
expression profile appear in red and sample correlate in larger distance are colored 
in blue (Figure 43). This distance matrix revealed that all samples derived from 
tumors previously passaged in mice (PC3-A3, PC3-D3 and PC3-D4) showed higher 
similarity to each other than the group of PC3-wt tumor samples which clustered in a 
different family in larger distance to the rest of the samples, indicating in vivo 
passaging effects. One PC3-A3 tumor could be identified as outlier by this method 
and was not included in further analysis. 
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Figure 43: Distance matrix of tumor samples obtained by divisive hierarchical clustering based on 
robust multichip analysis (RMA) data of microarray analysis from PC3 xenografts. Low distance is 
visualized in red and high distance is visualized in blue. Outliers are marked by * and are excluded 
from further data analysis  
3.2.8.2. Influence of in vivo passaging on gene expression of PC3 cells 
Differentially expressed genes between xenografts of previously in vivo passaged 
PC3-A3 and corresponding parental PC3-wt were determined using SAM and 
Spotfire Decision Site®. The corresponding Scatter plots in Figure 44 display 
average normalized log2 values of gene expression levels in PC3-A3 and 
corresponding PC3-wt tumors. Genes with a total lower expression are colored in red 
whereas highly abundant genes appear in blue. Genes which show significant 
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differences between the two groups of PC3 tumors appear in teal blue and are 
annotated by their gene symbols and are summarized in Appendix Table 6 (chapter 
6.1). 
The applied selection criteria (fold change > 2, p-value< 0.05) resulted in 10 genes 
with higher expression in PC3-A3 compared to parental PC3-wt tumors and in 125 
genes with lower expression compared to parental PC3-wt tumors (Figure 44, 
Appendix Table 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44: Scatter plot of PC3-wt compared to in vivo passaged PC3-A3 xenografts. The scatter plot 
display average normalized log2 values of gene expression levels of PC3- A3 tumors and the 
corresponding PC3-wt tumors. Genes with a total lower expression are colored in red whereas highly 
abundant genes appear in blue. Genes, which show significant differences between the two groups of 
PC3 tumors, are marked in teal blue and are annotated by their gene symbols (2 fold regulation;T-
Test: p< 0.05). 
 
3.2.8.3. Differentially expressed genes between resistant and non resistant 
tumors 
In order to detect differences in gene expression between resistant and non resistant 
PC3 xenografts, tumors from each resistant PC3 cell line (PC3-D3 and PC3-D4) 
were compared to appropriate control tumors derived from in vivo passaged non 
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resistant PC3-A3 cells. Due to the fact that PC3-D3 and PC3-D4 cells are derived 
from resistant tumors of two different animals their gene expression profiles were 
compared separately to control tumors in order to also incorporate gene expression 
differences specific for each of the resistant variants. 
Resistant PC3-D3 versus in vivo passaged PC3-A3 
Differentially expressed genes between in vivo PC3-D3 and PC3-A3 xenografts were 
determined and the corresponding scatter plot in Figure 45 displays the detected 
differences in gene expression profiles between PC3-D3 and PC3-A3 which show 
regulation >1.6 fold (p-value < 0.05). These selection parameters led to 34 genes 
with higher expression in resistant PC3-D3 compared to sensitive PC3-A3 tumors 
and in 12 genes with lower expression compared to PC3-A3 tumors (Figure 45, 
Appendix Table 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45: Scatter plot of PC3-D3 (resistant) compared to in vivo passaged PC3-A3 (sensitive) 
xenografts. The scatter plot display average normalized log2 values of gene expression levels of PC3-
D3 tumors and the corresponding PC3-A3 tumors. Genes with a total lower expression are colored in 
red whereas highly abundant genes appear in blue. Genes, which show significant differences 
between the two groups of PC3 tumors, are marked in green and are annotated (1.6 fold regulation; T-
test: p< 0.05). 
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Resistant PC3-D4 versus in vivo passaged PC3-A3 
Figure 46 shows differentially expressed genes (>1.6 fold; p-value < 0.05) between 
PC3-D4 (resistant) and PC3-A3 (sensitive) xenografts in a scatter plot. Setting 
selection parameters as described, revealed 26 up- and 30 down-regulated genes in 
resistant PC3-D4 tumors compared to PC3-A3 control tumors (Figure 46, Appendix 
Table 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46: Scatter plot of PC3-D4 compared to in vivo passaged PC3-A3 xenografts. The scatter plot 
display average normalized log2 values of gene expression levels of PC3-D4 tumors and 
corresponding PC3-A3 tumors. Genes with a total lower expression are colored in red whereas highly 
abundant genes appear in blue. Genes, which show significant differences between the two groups of 
PC3 tumors, are marked in green and are annotated (1.6 fold regulation; T-test: p< 0.05). 
Differences and similarities between two resistant PC3 cell lines 
Comparison of the two different resistant variants revealed that a set of 15 genes is 
commonly up-regulated in PC3-D3 as well as in PC3-D4 compared to non resistant 
PC3-A3 tumors. However, each variant has several genes which are significantly up-
regulated only in the respective tumors (19 genes in PC3-D3 and 12 genes in PC3-
D4) compared to PC3-A3 tumors (Figure 47A). Eight genes are down-regulated in 
both resistant tumors compared to non resistant PC3-A3 tumors but a set of 5 genes 
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(PC3-D3) respectively 23 genes (PC3-D4) is significantly lower expressed only in one 
of the resistant variants compared to PC3-A3 control tumors (Figure 47B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47: Differences and similarities between gene expression of resistant PC3-D4 and PC3-D3 
versus non resistant PC3-A3 tumors. (A) Up-regulated genes in resistant versus non resistant PC3-A3 
tumors. (B) Down-regulated genes in resistant versus non resistant PC3-A3 tumors.  
3.2.8.4. Influence of CPA on differential gene expression in PC3 tumors 
Influence of CPA on differences in gene expression between in vivo passaged 
PC3-A3 and parental PC3-wt tumors 
CPA induced stress provoked similar response in PC3-wt and PC3-A3 tumors 
towards the drug in terms of gene up-regulation. The only gene, detected to be 
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specifically up-regulated in PC3-A3 compared to paternal PC3-wt tumors under CPA 
treatment is GABRE. However, the number of genes down-regulated in PC3-A3 
tumors compared to PC3-wt increased significantly in response to CPA treatment (59 
specifically down-regulated genes in PC3-A3 compared to PC3-wt in response to 
CPA) (Figure 48).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: Influence of CPA on differences in gene expression between in vivo passaged PC3-A3 and 
parental PC3-wt tumors. (A) Genes up-regulated In PC3-A3 compared to PC3-wt. (B) Genes down-
regulated in PC3-A3 compared to PC3-w 
t
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Influence of CPA treatment on differences in gene expression between 
resistant and non resistant PC3 tumors 
The cytotoxic drug CPA resulted in different effects on gene regulations in PC3-D3 
and PC3-D4 tumors 24h after treatment. The influence of CPA on gene expression 
profiles in PC3-D3 compared to PC3-A3 resulted in specific up-regulation of eight 
and down-regulation of six genes in PC3-D3 compared to PC3-A3 (Figure 49). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: Influence of CPA on differences in gene expression between resistant PC3-D3 and in vivo 
passaged PC3-A3 tumors. (A) Genes up-regulated In PC3-D3 compared to PC3-A3 tumors. (B) 
Genes down-regulated in PC3-D3 compared to PC3-A3. 
+ CPA- CPA
ZNF91 
CST1 
ZNF737 
ZNF415 
IGF2 
REG4 
ZNF100 
ZNF43 
ZNF788 
ZNF117 
SATB1 
ZNF429 
SLC10A5 
ERV3 
CDH13 
ZNF257 
PROKR1 
ZNF625 
MSTN 
TMEM71 
SLC1A3 
GLB1L3 
ZNF91 
PASD1
ZNF711 
RP6-213H19.1 
ANKRD30A 
ESM1 
CALB1 
CDC20B 
ZNF492 
ZNF626
MPZL2 
ZNF66 
MBNL3 
CDH12 
TFF1 
ZNF486 
BCAT1 
GALNT14 
RBM35A 
NCAM2 
GPC4 
A
SSX1 
SCNN1G 
GABRE 
FAM172B 
CHRM3 
MME 
IL1RAPL1 
SSX8 
SH2D1B 
SCN3A 
SLAMF9 
APOL6 
BMPR1B 
+ CPA- CPA
NTS 
TCN1 
MAGEC2 
IL13RA2 
HCLS1 
PDPN
BMPR1B 
B
Results 65
CPA treatment specifically induced overexpression of 98 genes in resistant PC3-D4 
compared to PC3-A3 control tumors. Additionally 12 genes were down-regulated in 
PC3-D4 compared to PC3-A3 xenografts 24 h after CPA application (Figure 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: Influence of CPA on differences in gene expression between resistant PC3-D4 and in vivo 
passaged control PC3-A3 tumors. A) Genes up-regulated In PC3-D4 compared to PC3-A3 tumors. B) 
Genes down-regulated in PC3-D4 compared to PC3-A3. 
+ CPA- CPA
ZNF681 
IFNE1 
ZNF43 
ZNF91 
ZNF100 
ZNF492 
ZNF429 
ZNF682 
TNFAIP6 
CD274 
DEPDC1 
BCHE 
LOC388524 
ZNF117 
MGC9913 
ZNF675 
DHRS9 
LOC285550 
ZNF721 
ZNF345 
TFPI 
TMEM27 
SATB1   
CDC20B 
C17orf60 
GLB1L3 
TFF1 
NOG 
ZNF625 
MGC9913 
F3 
PASD1 
PRSS35 
RBM35A 
CDH13 
ZNF626 
ME1 
STAT1 
MPZL2 
ZNF486 
APOBEC3G 
ZNF260 
ZNF415 
LRRC39 
DNAJB4 
BDKRB1 
PTER 
SENP6 
TTK 
ZNF253 
TMEM156 
MMP13 
HOOK1 
SERPINI1 
LOC554202 
SLC7A6 
DKFZp451M2119 
SNORD58A 
ZNF382 
ZNF334 
LOC284702 
ANXA3 
SSX1 
MPHOSPH6 
SNORD20 
TTN 
NLGN1 
POLK 
COBLL1 
MSTN 
SNORD5 
ABCA11 
GPR126 
CCDC18 
SLC7A5 
PIGF 
WDR17 
CCDC102B 
LRRCC1 
MANEA 
BCAT1 
IBTK 
ZNF439 
GALNT3 
ABCA8 
SNORA20 
PMAIP1 
ZNF585B 
USP45 
FRK 
IFT74 
ZNF493 
TSGA10 
LYRM7 
LCORL 
NSBP1 
GCC2 
TAS2R50 
CLGN 
KLRA1 
SLC35A1 
TAS2R49 
CCDC112 
C5orf34 
ZNF737 
PIWIL1 
TEX15  
CADM2 
RPGRIP1L 
IPO11 
CCDC141 
ZNF788 
MBNL3 
ZNF66 
ODZ1 
RP6-213H19.1 
CDH3 
TGFB2
KIAA1333 
OTUD6B 
ZNF506 
ORC3L  
NFAT5 
SFRS18 
ZNF267
A
IL1RAPL1 
SCN3A 
ELMOD1 
FAM130A2 
KITLG 
MX1 
PLA2G4A 
MAGEC2 
SCEL 
SLC14A1 
NR2F1 
ORM2 
C13orf18 
CALCRL 
SCN2A 
HAS2 
+ CPA- CPA
NTS 
TCN1 
IL13RA2 
HCLS1 
BMPR1B 
PARP8
KCNJ6 
SSX1 
SERPINB7 
CHRM3 
PDE3A 
S100A2 
ARMCX3 
NAV3 
SRPX 
NR2F1 
GABRE 
IFIT1 
C13orf18 
MME 
HPGD 
CXCL6 
PRSS12 
PPP2R2C 
ASRGL1 
SH2D1B 
NTNG1 
B
Results 66
Beside the varying numbers of genes specifically regulated in response to CPA there 
are several genes in each group which are constitutively up- respectively down-
regulated in untreated as well as in CPA treated tumors (Figure 48-50). 
3.2.8.5. Gene Clustering  
Hierarchical gene clustering is a common method in array data analysis. It is a useful 
exploratory technique for gene-expression data as it groups similar gene expression 
pattern together and can hint to potentially meaningful relationships between single 
genes. In this study hierarchical clustering using open source software of Michael 
Eisen was applied (Eisen 1998). Selected clusters are presented in the following 
section. Green color indicates relatively lower gene expression whereas red color 
stands for relatively increased gene expression compared to the mean expression 
value.  
Gene cluster up-regulated in both resistant variants 
Figure 51 shows gene cluster including significantly up-regulated genes (red circle) 
in at least one resistant variant versus non resistant PC3-A3 tumors and genes with 
similar gene expression pattern to these selected genes. ANXA3, STAT1, SLC7A6, 
MBNL3 and ZNF486 are genes with significantly higher expression levels in at least 
one of the resistant subgroup and cluster in close proximity to a variety of other 
genes with similar gene expression pattern as indicated in Figure 51A. 
The genes TGFB2, CD274, TNFAIP6, GPR126, PMAIP1 and MPHOSPH6 all 
significantly up-regulated in PC3-D4 tumors under CPA treatment, cluster in close 
proximity. Clustering also revealed that expression levels were also increased in 
PC3-D3 compared to non resistant tumors however the up-regulation was not 
significant according to our selection criteria (Figure 51B). 
The third cluster in Figure 51 includes PASD1 and GALNT4 in the same family tree. 
Both are significantly higher expressed in resistant tumors than in their non resistant 
counterparts (Figure 51C). 
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Figure 51: Gene cluster showing higher expression levels in resistant PC3 xenografts than in non 
resistant PC3 xenografts. (A) Cluster including ANXA3, STAT1 and MBNL3. (B) Cluster including 
TGFB2 and CD274. (C) Cluster including PASD1 and GALNT4  
Gene cluster down-regulated in both resistant variants 
Hierarchical gene clustering also revealed gene clusters with relatively lower 
expression in resistant versus non resistant PC3 tumors. The five candidates 
ARMCX3, BMPR1, CHRM3, KCNJ6, TCN1 detected to be significantly down-
regulated in both resistant variants respectively one of them appear in a common 
cluster of regulation (Figure 52A). Another group of genes including MX1, IFIT1 and 
PDGFD also showed similar gene expression pattern (Figure 52B). 
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Figure 52: Gene cluster showing lower expression levels in resistant PC3 xenografts than in non 
resistant PC3 xenografts. (A) Cluster including ARMCX3, TCN1, BMPR1B, CHRM3 and KCNJ6. (B) 
Cluster including MX1, PDGFD and IFIT1. 
3.2.8.6. Tissue Factor (F3) – a candidate for alternative splicing in PC3-D4 
The GeneChip® Human Gene 1.0 ST Array offers whole-transcript coverage. Each 
of the 28,869 genes is represented on the array by approximately 26 probes spread  
across the full length of the gene covering all exons. Therefore it is possible to use 
this information in order to detect differentially expression on exon level. As there are 
only approximately two probes per exon these data have to be confirmed by RT-PCR 
of the corresponding tumor tissue. 
F3 is an example of varying exon expression pattern between different PC3 
xenografts. In this case exon 1 showed equal expression between all PC3 xenografts 
whereas exon 2-6 revealed higher expression in PC3-D4 xenografts compared to all 
other xenografts (Figure 53) 
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Figure 53: Relative Probe-level expression profile of F3 gene in PC3 xenografts. Expression values of 
PC3-D4 are presented in clear blue whereas expression values of other PC3 xenografts are presented 
in dark blue. Assignment of the individuals probes to exons 1 to 6 is indicated by the vertical lines in 
the expression profile and the gene model as defined by Affymetrix (dark blue) and Ensembl 
(orange)and the published transcript alternatives (clear blue) in the lower part of the figure. 
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3.2.8.7. A genomic point of view on candidates obtained by proteomics 
Combination of genomic and proteomic approaches provide complementary 
information about the same problem regarding at two different levels. In order to gain 
additional information about candidates identified in the proteomics study, gene 
expression of the three selected proteins ANXA3, TXNDC5, CatB and CK19 
differentially regulated in proteomic profiling of resistant (PC3-D3 and PC3-D4) 
versus non resistant PC3-wt and PC3-A3) cells has been selected for detailed 
analysis. Figure 54 shows gene expression profiles of ANXA3, TXNDC5, CatB and 
CK19 in different PC3 xenografts. CK19 mRNA did not reveal any significant 
regulation between different PC3 xenografts. The mRNA regulation of CatB reflects 
western blot data of in vivo tumor tissue where no statistically significant up-
regulation in resistant tumors versus non resistant control tumors could be detected. 
However a tendency of higher CatB levels in PC3-D4 could be detected. TXNDC5 
mRNA levels slightly decrease (not statistically significant) in resistant tumors in 
comparison to their non-resistant counterparts. In contrast, it is obvious that ANXA3 
is significantly up-regulated on mRNA level in the resistant PC3 xenografts compared 
to the non resistant controls. (Figure 54, compare Figures 31, 35-42 for protein 
expression data). 
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Figure 54: Gene expression profiles of proteomics candidates ANXA3, TXNDC5, CatB and CK19. 
Average normalized log2 gene expression is visualized over the different sample groups.
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4. Discussion 
4.1. Colon cancer 
4.1.1. Fragmentation of Lamin A/C in multicellular spheroid of low-passage 
colon carcinoma cells 
In the present work the low passage human colon cancer cells COGA-53 were 
cultured as multicellular spheroids to provide a model system that reflects the three-
dimensional structure of the respective tumor in vivo. The COGA-5 cell line was the 
only out of seven tested low passage colon cancer cell lines that generated fully 
compact multicellular spheroids. Further, the COGA-12 cell line formed partly 
compact multicellular aggregates with local areas of compaction. The COGA-12 
aggregates were additionally investigated in this work as representatives for a three-
dimensional cell culture model exhibiting a lower degree of compaction compared to 
the fully compact multicellular spheroids of cell line COGA-5. Proteome analysis 
revealed several alterations in the protein expression pattern of the COGA-5 
spheroids compared to the corresponding monolayer cultures. Five proteins were 
found to be up-regulated and one protein was down-regulated in spheroids compared 
to the monolayer culture. In COGA-12 partly compact aggregates, four proteins were 
found up-regulated compared to the respective monolayer. In the proteome 
comparisons between monolayers and the respective spheroids, only two-fold or 
higher alterations in protein expression were taken into account. This stringent 
analysis provided a highly reproducible detection of regulated proteins. However, this 
restriction significantly reduced the number of detected spots. Furthermore, the 
current analysis was restricted mainly to cytosolic proteins, whereas detection of 
hydrophobic membrane proteins or basic proteins was limited. 
The spots 12-A and 12-B both up-regulated in COGA-12 aggregates were identified 
as two isoelectric variants of acidic ribosomal protein P0. P0 is highly conserved in 
vertebrates and forms the lateral stalk of the 60S ribosomal subunit together with two 
hetero- or homo-dimers of acidic ribosomal proteins P1 and P2; P0 functions as 
ribosomal core protein for the anchorage of P1 and P290;91. This stalk is located at the 
active site of the ribosome particle, where interactions between mRNAs, tRNAs and 
translation factors take place during protein synthesis. Recently, Wu and Storey 
reported regulation of P0 depending on oxygen levels in frog brain tissue suggesting 
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a role of P0 in anoxia resistance92. The function of P0 up-regulation under anoxia, 
however, remains to be clarified. Hence, P0 might be up-regulated in COGA-12 
aggregates as a consequence of the lower oxygen supply in compact areas which 
are restricted from oxygen and serum supply. In addition, it was previously 
demonstrated that mRNA levels of P0 were increased in hepatocellular and colon 
carcinoma in accordance with increased biological aggressiveness, i.e. enhanced 
tumor outgrowth and cancer progression93;94. Overall, these data link altered P0 
expression to cellular stress as well as cancer cell proliferation which both are 
features in three dimensional cultures.  
The protein down-regulated in COGA-5 multicellular spheroids was identified as the 
acidic isoform of calponin, as also confirmed by immunoblot analysis. Calponins are 
actin-associated proteins and besides acidic calponin two other isoforms are known, 
namely basic and neutral calponins95;96. Basic calponin is the best studied isoform 
and is exclusively expressed in smooth muscle cells where it plays a role in the 
regulation of contraction97. Less is known about acidic calponin which is expressed in 
a wide variety of tissues, including the colon98. Acidic calponin is not involved in 
contraction99 but may play a role in cytoskeletal organization, since it binds to 
actin96;100. The down-regulation of calponin in multicellular spheroids therefore 
implies differences in cytoskeletal structures compared to monolayer cultures. In fact, 
changes in the tumor architecture of multicellular spheroids compared to the 
corresponding monolayers have been reported in a variety of tumor types including 
renal101, gastric6 and colorectal carcinomas102;103. Altered cell and nucleus shapes 
attributable to changes in cytoskeletal elements and nuclear structures are hallmarks 
of cancer cell morphology that may contribute to altered properties compared to 
normal cells104. It is likely that cells in multicellular spheroids represent such 
alterations of in vivo tumor cells better than monolayer cells.  
Another protein that was up-regulated in multicellular spheroids of COGA-5 cells was 
identified as 15-hydroxyprostaglandin dehydrogenase (15-PGDH). 15-PGDH 
mediates prostaglandin degradation105 and therefore prevents tumor promoting 
effects of prostaglandins106. For example, prostaglandins promote growth factor 
signaling and antagonize apoptosis106. Therefore, 15-PGDH is considered to expose 
tumor suppressor activity, since it may antagonize prostaglandin-mediated tumor 
progression. In multicellular spheroids 15-PGDH may contribute to proliferation 
inhibition, which is an established feature of multicellular spheroids where 
Discussion 75
proliferation is restricted to local areas85. In addition, the up-regulation of 15-PGDH 
as a potential tumor suppressor fits well with the observed lamin cleavage as a result 
of enhanced apoptosis rate in the multicellular spheroids. 
Proteome analysis revealed a 28 kDa fragment of the protein lamin A/C in COGA-5 
spheroids and low levels of this lamin A/C fragment were also detected in COGA-12 
partly compact aggregates but not in the respective monolayer cultures. Lamins are 
type V intermediate filament proteins that form the nuclear lamina, a filamentous 
network that connects the inner nuclear envelope membrane with chromatin107. 
Lamins form stable structures in the nuclear lamina and the nucleoplasm thereby 
determining nuclear shape and size, stability, and the position of nuclear pore 
complexes108-110. Furthermore, it has been suggested that lamins are involved in 
DNA replication and transcription107;111. In caspase dependent apotosis lamin A/C is 
cleaved by caspase-6 which is a requirement for the initiation of the nuclear events of 
apoptosis, e.g. condensation of chromosomal DNA and formation of apoptotic 
bodies112;113. Inhibition of caspase-6 and thus inhibition of lamin cleavage enables 
chromatin to fully condense leading to the suggestion that lamin cleavage frees 
chromatin from the lamina112. However, additional experiments performed in other 
studies in neuronal cells showed that caspase-6-dependent lamin A cleavage is not a 
general phenomenon in apoptotic cell death. For example, in a model of glutamate-
induced cell death in neuronal HT-22 cells we could not detect cleaved lamin A in the 
apoptotic cells14. In this model system the cells undergo caspase-independent 
apoptosis that is mediated by mitochondrial release of apoptosis inducing factor 
AIF114. Thus, the absence of lamin A cleavage serves as additional evidence for the 
lack of caspase-6 activation after glutamate-induced apoptosis.  
The detected truncation of lamin A/C in the spheroids may be a result of apoptotic 
stress induced by the lack of oxygen and growth factors. Our results clearly show that 
truncation of lamin A/C was induced in monolayer cultures by withdrawal of trophic 
support. Serum deprivation alone was sufficient for lamin A/C fragmentation and 
enhanced by simultaneous hypoxia, whereas hypoxia alone was not sufficient to 
produce the protein fragment. Using an antibody that only recognizes caspase-
cleaved lamin A and by pharmacological inhibition of caspases we could further verify 
that the detected lamin A fragment was indeed a product of caspase cleavage.  
Recent studies demonstrated that lamin A/C is a preferred substrate of caspase-6 in 
apoptotic cells86;115;116. Consistent with these previous reports, in our studies the pan 
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caspase inhibitor zVADfmk reduced lamin A/C cleavage in a dose-dependent 
manner. Furthermore, addition of a caspases-6-specific inhibitor to spheroid cultures 
of COGA-5 cells confirmed that caspase-6 is responsible for the cleavage of lamin 
A/C in spheroid cultures of the COGA cells. Thus, the results indicate that apoptosis 
is a feature of the investigated spheroids of low passage colon cancer cell lines. 
Similar findings were made with spheroids from other cancer cell lines117. Such 
apoptotic signaling involves the activation of caspases and cleavage of lamin A/C 
and may be triggered by reduced trophic support rather than hypoxia. In compact 
areas of multicellular spheroids, hypoxia may further amplify the apoptotic stress 
similar to the additive effect of hypoxia on lamin A/C cleavage in serum-deprived 
monolayer cultures. Interestingly, immunochemical analyses suggest a distribution of 
caspase-cleaved lamin A throughout the COGA-5 spheroid, not only in compact inner 
areas but also in cells in the outer layers. This finding correlates with results from the 
TUNEL assay indicating apoptotic cells in different areas in compact COGA-5 
spheroids. This leads to the assumption that apoptosis may take place not only in 
inner spheroid areas due to reduced trophic support and hypoxia. Another possibility 
is that apoptotic cells are transferred to outer regions of the spheroid instead of 
resting encapsulated within the spheroid.  
4.1.2. Chemoresistance in low passage colon cancer cells 
Differences in protein expression as observed in the 5-FU resistant cells compared to 
the original COGA-12 cells could result from genetic deletion, altered protein 
synthesis or increased degradation of the protein. The present results from RT-PCR 
analysis revealed reduced mRNA levels in 5-FU chemoresistant COGA-12/COGA-
12/G6 cells versus COGA-12 cells, strongly indicating that the previously detected 
down-regulation of Hsp27 protein in COGA-12/G6 cells resulted from altered protein 
synthesis at the transcriptional level. Hsp27 is subjected to regulation by both heat 
shock transcription factors (HSFs) and by post-translational modification through 
phosphorylation at serine-residues of the protein, for example by MAP-kinase 
activated protein, and protein kinases C or D, after various forms of extracellular 
stress. Such phosphorylation seems to be very important for structure and function of 
Hsp27, for example regulating its chaperone function or the quaternary structure of 
the protein118. However, in the COGA-12/G6 cells down-regulated Hsp27 levels are 
more likely attributable to the HSFs which can reduce mRNA levels of Hsp27119. The 
observed mRNA down-regulation hence opens up the possibility that Hsp27 is 
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involved in the 5-FU resistance mechanism and is not due to long term culturing. 
Since reduced mRNA levels were detected in COGA-12/G6 cells but not in COGA-
12/NO cells which represent corresponding long term passaging control cells without 
chemotherapeutic stress. As the down-regulation of Hsp27 is still present after 
several passages in vitro without chemotherapeutic stress, it can also be concluded 
that down-regulation of Hsp27 seems to be consistent over time in the COGA-12/G6. 
In order to clarify if the lower levels of Hsp27 have any functional relationship with the 
observed chemoresistance in COGA-12/G6, a siRNA knockdown approach was 
chosen. Down-regulation of Hsp27 in the non resistant COGA-12 cells neither with 
the HSP27 single sequence siRNA87 nor with a corresponding Dicer product resulted 
in higher chemoresistance of these cells towards 5-FU. As the results of the 
corresponding RT-PCR showed, this could not be due to an insufficient knockdown 
effect, as both single sequence siRNA and Dicer product showed remarkable 
knockdown of Hsp27 mRNA level. Therefore it is more probable that HSP27 down-
regulation in the COGA-12/G6 cells is at least not one of the causative events 
relevant for the 5-FU resistance. As it is described that HSP27 up-regulation has a 
protective role against chemo-induced cell death in many resistant tumor cells it is 
possible that down-regulation of this protein is just a consequence of other processes 
in COGA-12/G6 cells and maybe due to lower stress levels in these cells or that 
alternative proteins have taken over the function of Hsp27120. 
There are many modes of resistance to 5-FU. 5-FU itself does not have cytotoxic 
effects, but its metabolites FdUMP, FdUTP, FdUTP and FUTP which compete with 
the corresponding uracil metabolites for incorporation into RNA. In addition, FdUMP 
binds to thymidylate synthase and thereby inhibits its enzyme activity, by inhibiting 
the generation of deoxythymidine triphosphate (dTTP) that is required for DNA-
replication121. One of the most common resistance mechanisms of 5-FU is increased 
expression of thymidylate synthase25;121. 
Therefore the mRNA level of thymidylate synthase was compared between resistant 
COGA-12/G6 and parental COGA-12 cells. Increased levels of thymidylate synthase 
mRNA were observed in the 5-FU resistant COGA-12/G6 cells, indicating that this 
might at least be one key player in the 5-FU resistance of the COGA-12/G6 cells. 
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4.2. In vivo chemoresistance of prostate cancer in metronomic 
cyclophosphamide therapy 
4.2.1. A non classical mechanism of chemoresistance in vivo 
In the present work, acquired in vivo chemoresistance against metronomic 
cyclophosphamide treatment was studied in a human prostate cancer xenograft 
model. The observed tumor growth profile exhibited two phases. In the first phase 
(response-phase), tumor progression was significantly suppressed by therapy and 
tumor volume remained constant. After 50 days of tumor cell implantation and about 
40 days of treatment, tumor volumes increased despite ongoing CPA therapy 
(escape-phase) (Figure 5B). Two tumor cell lines (PC3-D3) and (PC3-D4) were 
obtained from two different resistant tumors and one cell line (PC3-A3) was isolated 
from an untreated non resistant control tumor. 
As CPA is a prodrug, which has to be metabolized by liver cytochrome P450 
enzymes122 and the therapeutic approach reveal antiangiogenic properties several 
escape mechanisms come into direct consideration. On one hand, prolonged CPA 
treatment might result in decrease of liver capacity in terms of drug bioactivitation, 
resulting in decrease of systemically available active metabolites. On the other hand, 
as metronomic CPA therapy exhibits antiangiogenic activity, development of 
alternative, non-angiogenesis dependent forms of blood supply (vasculogenic 
mimicry52;53) come into consideration to revoke tumors from efficient therapeutic 
response47. In line with previous studies, tumor blood flow analysis demonstrated a 
reduced functionality of tumor vessels in CPA treated tumors at the treatment 
endpoint, indicating still effective conversion of CPA to the cytotoxic active drug after 
prolonged treatment (Figure 6C versus D;E). Analysis of laminin, which is a main 
compound of the basal lamina of blood vessels, and staining for CD31 positive 
endothelial cells showed co-localization in treated as well as in untreated tumors 
(Figure 6C versus D). Total count of mouse CD31 positive structures, representing 
functional as well as non functional vessel structures within tumor tissue, was not 
significantly reduced by the therapeutic regimen. However, decreased functional 
blood flow was detected to go along with a reduced number of vessels with 
detectable lumen (Figure 6E). Therefore it seems unlikely that lacking 
responsiveness in the second period of treatment is due to insufficient CPA 
biotransformation followed by non effective suppression of angiogenesis. This is 
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consistent with recently published pharmacodynamic and pharmacokinetic studies of 
prolonged low-dose CPA therapy122 and further suggests that re-growth of tumors is 
not due to malfunction of antiangiogenic scheduled CPA e.g. by non efficient 
activation of the pro-drug in the liver. Further histological analyses of collected tumor 
tissue, comparing relapsing CPA treated tumors and untreated control tumors 
resulted in a similar tissue structure; however, treated tumors exhibited larger areas 
of condensed and fragmented cell nuclei, probably resulting from direct cytotoxic 
effects of CPA and/or by microenvironmental effects resulting from decreased blood 
supply78.  
To give further consideration to possible resistance mechanism resulting from 
metronomic scheduled CPA treatment, immunohistochemistry of tissue from 
reimplanted tumors was performed in combination with respect to functional blood 
flow. Blood flow analysis of reimplanted resistant tumors revealed no significant 
differences in comparison to the in vivo passaged PC3-A3 control tumor, indicating 
that resistant tumors do not compensate the antiangiogenic treatment by exhibition of 
increased angiogenic potential (Figure 30A). Further on, the following short term 
treatment for 14 days resulted in a similar response in terms of blood flow in resistant 
and control tumors. In resistant tumors and in PC3-A3 control tumors two cycles of 
CPA application were not sufficient for statistically significant changes in tumor blood 
flow (Figure 30A). As therapeutic strategies targeting preferentially endothelial cells 
would not be effective in tumors whose blood supply is formed in the absence of 
angiogenesis, tumor microsections were analyzed for the existence of alternative 
blood supply routes (vasculogenic mimicry). These functional routes are 
characterized by tumor cells generating microcircular channels composed of 
extracellular matrix, including laminin and lined by tumor cells in the absence of 
endothelial cells52;53. The existence of such channels was already described for 
different Dunning rat prostatic adenocarcinoma cell lines as well as for the human 
cancer line DU145123. However, in the PC3 xenograft model, CD31/laminin co-
staining revealed that all functional vessel structures, indicated by Hoechst 
fluorescene, showed a positive reaction for CD31 on the lumen internal surface. 
Functional microvascular channels without participation by endothelial cells could not 
be detected in the resistant tumors even under therapeutic pressure (Figure 30B).  
Reisolated resistant ( PC3-D3 and PC3-D4) and in vivo passaged control tumor cells 
(PC3-A3) were characterized and identified in terms of cell morphology and their 
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human receptor status in order to distinguish them from mouse derived cells. No 
differences in cell morphology or epidermal growth factor (EGF) receptor or 
transferrin receptor expression were detected by comparing reisolated tumor cells 
with PC3-wt cells78 (Figure 24, 25) 
In vivo chemoresistant, reisolated tumor cells (PC3-D3 and PC3-D4) did not manifest 
their drug resistant phenotype in two-dimensional monolayer culture, when treatment 
was performed with 4-HOO-CPA, indicating the involvement of microenvironmental 
factors (Figure 5C) and suggesting resistance mechanisms which differ from 
classical mechanisms based on up-regulation of drug efflux pumps48. Indeed, 
Hoechst efflux assay revealed that PC3 cells do not have a side population with 
increased efflux transporter activity124. Further on, the assay did not detect any 
differences between resistant and non resistant PC3 control cells (Figure 26) 
indicating that increased drug efflux is not relevant for resistance in this case.  
Importantly however, resistant tumor cells have an endogenous component crucial 
for in vivo resistance as the acquired drug resistant phenotype of reisolated tumor 
cells (PC3-D3 and PC3-D4) was manifested after reimplantation into mice (Figure 
28) even in the first phase of CPA treatment. Reisolated PC3 control tumor cells 
passaged in vivo without CPA treatment (PC3-A3) remained sensitive to the 
treatment regimen (Figure 29). Chemosensitivity of PC3-A3 cells exclude that 
resistance is acquired by unspecific selection processes of the in vivo tumor 
environment which may change the behavior independently of the applied 
chemotherapeutic regimen125;126. 
4.2.2. Proteomics and Genomics: two complementary approaches to in vivo 
resistance  
As no classical tumor escape mechanism could be detected to be responsible for in 
vivo resistance of PC3 xenografts towards metronomic CPA therapy, the analysis 
had to be continued on a more global level to discover new resistance mechanisms. 
In order to address the complexity of the system a proteomic as well as a genomic 
approach have been chosen as two alternating approaches to identify new 
candidates involved in resistance.  
4.2.2.1. Proteomic approach 
Proteome analysis by 2D DIGE revealed several alterations in protein expression 
pattern of reisolated cell lines PC3-D3 and PC3-D4 compared to corresponding 
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parental PC3-wt. From 25 relevant spots detected by 2D-DIGE, all could be assigned 
and recovered from preparative CBB-stained gels. All of these proteins could be 
identified by MALDI-PMF and MS/MS analysis on basis of commonly accepted 
database search criteria. In proteome comparisons between resistant and respective 
parental PC3-wt cells, only 1.6-fold or higher alterations in protein expression were 
taken into account, to keep the false discovery rate low. The identities of all identified 
spots are shown in Table 3, 4. Expression levels of four proteins were found to be 
increased and three proteins were down-regulated in PC3-D3 cells compared to 
parental PC3-wt cells (Figure 31A). In the PC3-D4 cultures, nine proteins were found 
up-regulated and nine down-regulated compared to parental PC3-wt (Figure 31B). 
Some alterations such as upregulation of keratin 8 and down-regulation of HSPD1 
(60kDa mitochondrial heat shock protein) were also present in in vivo passaged non 
resistant control cells, indicating regulations by microenvironmental influences. These 
alterations in protein pattern were excluded from further investigation as their 
regulations are independent from the therapeutic treatment regimen (Figure 32, 
Table 5). As both resistant sublines PC3-D3 and PC3-D4 are derived from different 
animals with resistant tumors, they do not have mandatory exactly the same 
resistance mechanisms activated. We assume that resistance towards 
antiangiogenic treatment is a complex process not only mediated by one distinctive 
molecular pathway. Therefore we analyzed two different clones in order to identify 
some common key proteins regulated in different resistant tumors in response to 
metronomic CPA therapy. We focused on ANXA3, TXNDC5, CatB and CK19. These 
candidates were identified by their differential expression profiles in both resistant 
variants compared to the chemosensitive controls (Figure 31C).  
Validation: Removal of false friends 
One protein detected to be regulated in both chemoresistant PC3 cell lines was 
identified as cytokeratin 19 (spot D3-3 and D4-1). Cytokeratin 19 is part of one group 
of intermediate filament proteins responsible for the integrity of cell structure, and 
have been reported to play a role in conferring a drug resistance phenotype in 
several types of cancer such as breast and cervical carcinoma127;128. However, in 
contrast to 2D-DIGE analysis, up regulation of this protein was not evident in the 
validation experiments by western blot analysis (Figure 33, 34) 
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Cathepsin B: where to B(e)?  
The catB spot regulated in both reisolated sub-lines (D3-4 and D4-5) has a molecular 
weight around 20-25 kDa and a pI value of 5.2 (Figure 31, Table 4, 5). Validation 
experiments by western blot analysis in vitro confirmed increase in catB in resistant 
compared to non resistant tumor cells detected by 2D-DIGE (Figure 35). No 
significant increase in protein level could be confirmed in corresponding tumor 
tissues (Figure 37). CatB is part of the class of cystein proteases, which belong to 
the papain family. The cystein proteases are predominantly endopeptidases, which 
are located intracellularly in endolysosomal vesicles. CatB can act as both 
endopeptidase and exopeptidase and is expressed constitutively participating in 
protein turnover. Cystein cathepsins are highly up-regulated in a variety of cancers by 
mechanisms ranging from gene amplifications to post-transcriptional modification. 
Their localization within intracellular lysosomes often changes during neoplastic 
progression, resulting in secretion of both inactive and active forms and association 
with binding partners on the tumor cell surface. Secreted, cell surface and 
intracellular cystein cathepsins function in proteolytic pathways that increase 
neoplastic progression129;130, and are also described to be promising markers for 
aggressive prostate cancer131. 
The spot up-regulated in PC3-D3 and PC3-D4 has a lower molecular weight and 
different pI from full length cathepsin b protein representing a variant for catB arising 
either from the use of alternative promoters or alternative splicing e.g. by exon 
skipping132 . Truncation in catB sequence often results in altered localization of the 
protein to different membraneous organelles133 and several studies describe that 
exon 2 and 3 can be skipped resulting in a shorter form of catB targeting 
mitochondria134 where it can influence the apoptotic pathway135. This finding is 
consistent with our observation that the two detected cathepsin forms of 32 kDa and 
22 kDa translocate to the mitochondria in the reisolated PC3 cells but not in the PC3-
wt cells in vitro (Figure 36). Nevertheless the role of catB in mitochondria in this case 
has to be clarified in future studies. 
TXNDC5: less is more? 
The spot D3-5 (1.6-fold down regulated) in the PC3-D3 cells and the spots D4-13 and 
D4-14 (both 1.8-fold down regulated) in the PC3-D4 cells were identified as TXNDC5 
(Figure 31, Table 4, 5). The spot D3-5 and D4-14 have the same position in the gel 
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whereas the D4-13 has a lower pI and a difference in molecular weight compared to 
the other spots of approximately 1 kDa. Peptide sequence comparison identified lack 
of peptides of the signal peptide at the N-terminus of TXNDC5 in the sequence of D4-
13, which might explain the lower pI value. Molecular weight difference might be due 
to posttranslational modification of the protein or represents a different isoform. 
TXNDC5 belongs to the protein superfamily of thioredoxin proteins. Thioredoxin (Trx) 
family members play critical roles in regulation of cellular redox homeostasis136;137, 
their role is widespread. It is described that they play a crucial role in increased 
proliferation, resistance to cell death and increased angiogenesis137. TXNDC5 is a 
protein disulfide isomerase (PDI) mostly located in the endoplasmatic reticulum138. 
TXNDC5 is especially present in endothelial cells where it protects the cells against 
apoptosis induced e.g. by hypoxia or chemotherapeutics139;140. In cancer cells its up-
regulation was associated so far with colon and hepatocellular carcinogenesis141;142. 
In our study the TXNDC5 protein was found to be down-regulated in both resistant 
sub-lines compared to PC3-wt cells in vitro. This could also be confirmed by western 
blot analysis in vitro (Figure 38) and in vivo (Figure 39). As our findings using 
hypoxic in vitro conditions do not correlate with the increased levels of TXNDC5 
under hypoxia observed by Sullivan et al. in endothelial cells where it is protective 
against hypoxia- induced apoptosis139, TXNDC5 must play a different role in PC3 
cells (Figure 38). It is described that PDIs can not only have chaperone function but 
also can exhibit the contrary in case of low concentrations compared to the unfolded 
substrate. Under these circumstances its role changes from preventing protein 
aggregation to promoting protein aggregation which finally leads to increased 
secretion of these proteins143. In our case of in vivo resistance where the cross talk 
between tumor and its microenvironment might be involved in resistance this role of 
TXNDC5 can be more important than its chaperone function. Chemotherapy resulted 
in significantly increased levels of TXNDC5 in the PC3-D3 tumor xenografts of the 
resistant PC3 cell lines whereas its expression was not affected in the 
chemosensitive tumors (Figure 39). As the induction of TXNDC5 under therapy is 
specific for resistant PC3 tumors it seems to be unlikely that its role is implicated in a 
general chaperone function under stress but a more specific role in 
activation/inhibition of resistance mediating signaling proteins by disulfide 
isomerization144. 
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ANXA3: a functional key player in metronomic chemoresistance in vivo? 
ANXA3 (D3-1 and D4-3) was up-regulated in both resistant sub-lines (Figure 31, 40). 
Western blot analysis from the corresponding tumor tissues showed that this effect is 
relevant under in vivo conditions. Additionally performed cross reactivity tests 
revealed that the detected regulation of ANXA3 is not influenced by potential 
changes in the content of mouse cells within the tumor tissue (data not shown). The 
protein levels even increase under therapy in PC3-D3 and PC3-D4 (resistant) but not 
in PC3-A3 control tumors (in vivo passaged), further indicating the involvement of this 
candidate in the in vivo resistance mechanism (Figure 41). ANXA3 is a member of 
the annexin family (I-XIII). All annexins have a conserved core domain consisting of 
four or eight annexin repeats, through which annexins binds to the phospholipids in a 
Ca2+-dependent manner145. ANXA3 is one of the least studied members and its 
function is widely unknown. It can mediate membrane-membrane contact during 
biological processes (i.e., phagosome-lysosome fusion, vesicular trafficking, plasma 
membrane binding and degranulation)146 and can interfere with arachidonic acid 
inflammation pathway147. Furthermore it is described as chemoattractant for 
macrophages148. Its role in cancer is still not fully understood. However, a proteomic 
study showed that ANXA3 might be implicated in response of lung cancer cells to the 
cytotoxic drug OSU03013, a derivative of celecoxib, and overexpression of ANXA3 
was detected in platinum-resistant human ovarian cancer cells149;150. With respect to 
the anti-angiogenic therapeutic schedule of our study ANXA3 could be considered to 
attribute to regulation of angiogenesis as it is proclaimed by Park et al. in an in vitro 
model151. However, we could not detect a statistically significant increase in 
angiogenic potential of resistant tumors. Our in vitro studies under hypoxic conditions 
showed increased expression of ANXA3 but without any difference between resistant 
and non resistant PC3 cells (Figure 42). This finding does not reflect the protein 
expression profile of ANXA3 in vivo, leading to the conclusion that resistance in vivo 
includes mechanisms going beyond direct hypoxia-induced regulations. Regarding at 
this discrepancy between in vivo and in vitro cell behavior the role of ANXA3 in 
inflammation and in outward cell signaling attracts notice to its role in tumor host 
interactions. In this context, the xenograft model provides the required environment 
for in vivo acquired drug resistance towards metronomic CPA therapy. 
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4.2.2.2. Genomic approach 
Microarray analysis was performed of tumor tissue (4 mice per group) derived from 
resistant (PC3-D3, PC3-D4) and non resistant PC3 (PC3-A3, PC3-wt) xenografts, 
either in the absence or presence of CPA therapy (24 h before tumor harvesting).  
Data analysis by hierarchical sample clustering revealed major variance in total gene 
expression between PC3-wt on the one hand and all other in vivo passaged tumors 
(PC3-A3, PC3-D3 and PC3-D4) on the other hand (Figure 43). This indicates the 
large influence of in vivo environment on tumor gene expression already previously 
described in several studies 126;152;153. Genes up-regulated by in vivo passaging in 
PC3-A3 compared to PC3-wt include e.g. podoplanin, IL13RA2, S100A2 which have 
been associated with aggressiveness, increased proliferation and migration of tumor 
cells154-156. Dow-regulated genes due to in vivo passaging include a variety of tumor 
suppressor genes such as e.g. TP53INP1 and LOX157;158 (Figure 44, Table x) . 
These observations on genetic level are sustained by our data showing a more 
aggressive tumor growth of PC3-A3, PC3-D3 and PC3-D4 in vivo compared to PC3-
wt tumors (Figure 29). These genes did not correlate with resistance in PC3 
xenografts as PC3-A3 tumors are still chemosensitive towards metronomic CPA in 
vivo (Figure 29) and up-regulated genes of aggressive tumor growth such as 
podoplanin, IL13RA2 and S100A2 did not keep their higher gene expression 
compared to PC3-wt under CPA treatment (Figure 48).  
With respect to the in vivo passaging effect, gene expression of resistant tumors has 
been compared to PC3-A3 in order of identify resistance relevant genes. These 
studies revealed innate alterations in mRNA levels between resistant and non 
resistant tumors (Figures 44-46). Analogue to results obtained by proteomic 
approach, both resistant tumors showed common alterations in gene expression as 
well as clone specific ones reflecting their origin from different resistant tumors 
(Figure 47). The majority of genes with constitutive differential expression between 
resistant and non resistant tumors kept their significant regulation after CPA 
treatment. Expression levels of several genes further increased respectively 
decreased after therapy. CPA treatment induced a variety of additional changes in 
gene expression between resistant and non resistant PC3 tumors (Figures 48-50, 
Apendix Tables 6-8). Especially in PC3-D4 tumors the fraction of candidates 
selectively up-regulated by CPA therapy exhibited to be outsized (Figure 50). 
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In line with our previous experiments, differentially expressed genes between 
resistant and non resistant PC3 tumors did not hint directly towards any classical 
resistance mechanism described so far. However, the gene expression profiles of 
several gene candidates could be linked to these of other genes with similar 
expression pattern via hierarchical gene clustering84. This could hint to their 
involvement in common pathways and provides interesting information for further 
detailed analysis of the candidates.  
 
ANXA3, already detected by proteomics to be up-regulated in resistant tumors, 
showed similar gene expression pattern to a cluster of genes especially highly 
expressed in PC3-D4 tumors but also showing higher expression in PC3-D3 tumors 
compared to non resistant PC3-A3 and PC3-wt tumors (Figure 51A). In addition to 
ANXA3 this cluster includes the significantly regulated candidates STAT1, SLC7A6, 
MBNL3 and ZNF486. ANXA3 clusters in close vicinity to the transcription factor 
NFATC3. NFATC3 is involved in Ca2+/calmodulin dependent transcription regulation 
promoting prostate cancer cell proliferation159 and its inhibition can led to apoptosis in 
retinoblastoma cells160. STAT1 has been described as key modulator in apoptosis 
resistance in response e.g. to radiation and cytotoxic stress in renal carcinomas and 
head and neck cancer cells161;162. It mediates the responsiveness of cells to several 
cytokines and growth factors and can be induced by INF signaling163. The 
involvement of ANXA3 and STAT1 in Ca2+ dependent signaling might be the link 
between both candidates164-166. STAT1 clusters in proximity to EMP-2 which has bee 
described to play a role in integrin receptor regulation in endometrium and has been 
associated with poor outcome of endometrial adenocarcinoma167;168. In mice, 
inhibition of EMP2 significantly reduced tissue production of inflammatory cytokines, 
recruitment of polymorphonuclear leukocytes, and local tissue inflammation169. 
Despite there is no clear link towards a well known resistance pathway; all these 
candidates can be associated to cytokine signaling. Thus this clustering can hint to 
the involvement of cytokine signaling and STAT1 mediated apoptosis resistance 
mechanisms in PC3 tumor resistance in vivo. 
 
Regarding at a second cluster of genes with up-regulated gene expression pattern in 
resistant versus non resistant PC3 tumors further hints towards involvement of 
inflammatory cytokine signaling in the resistance mechanism of PC3 tumors (Figure 
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51B). The cluster which groups around TGFB2, a candidate up-regulated in both 
resistant PC3 tumors under CPA therapy (especially PC3-D4) includes five other up-
regulated genes (significant regulation in PC3-D4) such as CD274, TNFAIP6, 
GPR126, PMAIP1 and MPHOSPH6. TGFβ has been described as a key player in 
angiogenesis as well as in inflammation and tissue repair170 Impaired calcium 
signaling can induce TGFβ171. Secreted TGFB2 has shown to effectively activate 
NFkappaB mediated apoptosis resistance in PC3 cells which can be overcome by 
targeting TGFB2 mRNA using siRNA172. It has been previously described that TGFB 
directly influences expression of CD274173. As these two proteins cluster in direct 
proximity an involvement of both within the same pathway therefore might be 
probable. CD274 is involved in inflammatory cytokine signaling174. Similar to STAT1, 
CD274 is also involved in interferon signaling175 and its overexpression is associated 
with a higher risk of relapse in Wilms Tumors176. Gene expression profiles of 
TNFAIP6 and GPR126 also show high similarity to that of TGFB2. GPR126 is a G-
protein cell surface receptor mostly described in endothelial cells which has been 
associated with cell adhesion and inflammation177. TNFAIP6 encodes TSG-6, a 35 
kDa inducible secreted glycoprotein. Activation of the TNFAIP6 gene by pro-
inflammatory cytokines, presence of TSG-6 protein in inflammatory lesions and its 
anti-inflammatory effect suggest a role for TSG-6 in a negative feed-back control of 
the inflammatory response178. It was shown that treatment of a murine macrophage 
cell line with TNFAIP6 protein up-regulates the expression of inducible 
cyclooxygenase-2 (COX-2), a key enzyme in inflammation and immune responses179. 
TSG-6 has been observed to directly interact with BMP-2 a component of the 
TGFB/BMP pathway in vitro180. 
 
A third cluster includes the candidates PASD1 and GALNT4 up-regulated in both 
resistant PC3 variants which cluster together in the same subfamily making them 
interesting candidates for following pathway analyses (Figure 51C). Both candidates 
are still poorly described in terms of their biological function. However, PASD1 has 
been previously associated with poor prognosis in B-cell lymphoma. The nuclear 
localization sequence and leucin zipper domain of PASD1 promotes the presumption 
that it plays a role as transcription factor181. GALNT4 belongs to the family of N-
acetylgalactosaminyltransferases which are key enzymes in O-glycolsylation of 
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different glycoproteins and have been recently shown to be relevant for TGFβ 
signaling182. 
 
Genes with decreased expression levels in resistant compared to non resistant PC3 
xenografts can also be grouped by hierarchical gene clustering. Figure 52A shows 
similar gene expression pattern for ARMCX3, TCN1, BMPR1B, CHRM3 and KCNJ6 
along with a set of other genes of similar expression profile. Activated BMP signaling 
has been described to show reduction in tumor growth of subcutaneous PC3 tumors 
in mice183. Therefore down-regulation of BMPR1B, a receptor involved in the BMP 
signaling cascade, in resistant PC3 tumors hints towards an inactivation of this 
growth control pathway. There is no clear link described so far between BMP 
signaling and other genes within this cluster. ARMCX3 also known as armadillo 
repeat-containing protein is a member of the outer mitochondrial membrane and 
interacts with Sox-10 a nuclear cytoplasm shuttle protein and transcription factor184. 
CHRM3 codes for an acetylcholine receptor185 and KCNJ6 codes for a G protein-
activated inward rectifier potassium channel 2 (GIRK2). Inhibition of GIRK channels 
appears to result, at least in part, from activation of phospholipase C (PLC) and the 
resultant decrease in membrane levels of phosphatidylinositol-4,5-bisphosphate 
(PIP2), an endogenous co-factor necessary for GIRK channel activity186. BMP 
signaling is also associated with intracellular Ca2+ pathways such as Ca/Calmodulin 
pathway and a cross talk of BMP signaling with the JAK/STAT pathway has been 
described187;188. 
 
The majority of genes included in a second cluster with a profile of lower gene 
expression in resistant versus non resistant variants can be associated to interferon 
signaling (Figure 52B). MX1, TRIM21, TRIM 5, OAS3 and IFIT1 are all genes which 
are normally induced by interferons in response to viral infection189. However, these 
factors have been shown to modulate not only antiviral response but also to play a 
role in cellular growth control, protein turnover and induction of apoptosis190-192. It is 
not clear yet how PDGFD can be related to these Interferon induced effectors. 
PDGFD is known to code for platelet-derived growth factor D which is a member of 
the PDGF/VEGF family of growth factors involved in a variety of cellular processes 
such as cell proliferation, invasiveness and angiogenesis. PDGFD has been 
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implicated in macrophage attraction193 and endothelial mesenchymal transition of 
PC3 cells194. 
 
Even if hierarchical gene clustering did not reveal a clearly defined pathway, it 
provided first evidence of the involvement of impaired Ca2+ and interferon signaling 
as well as a role of TGFB2 in prostate cancer CPA resistance in vivo. Each of the 
three pathways has been described independently from each other to be involved in 
apoptosis resistance of androgen independent prostate cancer 172;195-197. However, 
there are still open questions how they play together in mediating resistance to 
metronomic CPA therapy in vivo and it will be interesting to further analyze the 
connection between these three pathways and to clarify their detailed involvement in 
CPA resistance in vivo (Figure 55). As all three pathways are also associated with 
inflammatory cytokine signaling an involvement of tumor host interaction might also 
be relevant in this process198;199. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: Schematic view of possible mechanisms involved in prostate cancer resistance towards 
metronomic cyclophosphamide in vivo  
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Probe design of the Gene 1.0 ST Array System where each of the well-annotated 
genes is represented by  26 probes on average, spread across the full length of the 
gene, makes this array suitable also for a more detailed view on transcript level. The 
information about differences in expression of single exons can hint towards 
alternative splicing instead of whole gene regulation. F3 was one example where 
altered expression levels in different exons were detected specifically in resistant 
PC3-D4 compared to all other tumors. F3 codes for the tissue factor (TF) classically 
described as anti-coagulation factor. Tissue factor is overexpressed in a variety of 
cancers including prostate cancer200 and has been associated with tumor growth and 
angiogenesis201. In addition to the normal full length F3 transcript which was 
constitutively expressed in all PC3 tumors, a transcript variant could be detected to 
be up-regulated in PC3-D4 which showed only higher expression of sequences 
binding the probe set spanning exon 2-6 (Figure 53). Up to date two variants of 
alternative splicing have been described. Alternative splicing in terms of exon 5 
leading to a soluble form of TF (asTF) has been described to play a role in blood 
clotting202. More recently a splice variant was discovered to be present especially in 
solid tumors in addition to the normal full length F3. This variant describes an 
enlarged F3 transcript due to insertion of an exon 2 flanking sequence of intron 
1203;204. However no transcript variant lacking exon 1 has been described in the 
literature so far. Therefore it would be important to further validate this observation by 
PCR using an appropriate set of primers. 
4.2.2.3. Gene expression of proteomic candidates 
ANXA3, TXNDC5, CatB, three candidates for resistance detected by 2D-DIGE were 
studied in detail regarding their mRNA regulation by microarray analysis. Thus it 
could be determined if protein regulations were due to posttranslational modifications 
or to differences in mRNA levels. Gene expression of CK19, a protein also identified 
by proteomics but which could not be further confirmed as relevant for resistance was 
also analyzed in comparison to the other candidates. 
TXNDC5 which is down-regulated on protein level in resistant tumors shows only a 
tendency of lower gene expression in resistant variants compared to non resistant 
ones (Figure 54). As the difference in gene expression is not significant, there must 
be another posttranslational component involved in the lower protein expression of 
TXNDC5 within the resistant cells. Indeed two separate spots of TXNDC5 appeared 
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in the proteome of PC3-D4 cells which can hint to a posttranslational modification of 
this protein (Figure 31B, Table 4). 
CatB was significantly up-regulated on protein level in resistant PC3 cells compared 
to non resistant cells in vitro but could not be detected to be significantly increased in 
vivo by western blot analysis. Gene expression is also not significantly increased in 
both resistant variants but showed similar pattern to protein expression data of tumor 
tissue in vivo (Figure 54 versus Figure 37) where a non significant tendency of 
higher CatB expression in PC3-D4 tumors can be detected. In terms of its role in 
resistance the mitochondrial localization might be more interesting to investigate in 
detail than simple up-regulation of the gene. 
Figure 54 shows that gene expression of ANXA3 is strongly up-regulated in resistant 
compared to non resistant PC3 xenografts. This link of mRNA level and protein level 
makes ANXA3 an interesting candidate for siRNA knockdown in vivo. Interestingly, 
gene expression of ANXA3 is also increased in the PC3-A3 compared to the PC3-wt 
tumors however this regulation on mRNA level was not detected by western blot 
analysis on protein level of corresponding tumors (Figure 54 versus Figure 41).
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5. Summary 
Resistance in tumor therapy with chemotherapeutic drugs is still a major issue in 
cancer treatment and escape mechanism behind are far from being clear. Especially 
cancer resistance in vivo has been identified to be highly complex and not clarified in 
detail205. Mechanisms behind escape from antiangiogenic treatment approaches, a 
phenomenon which has been long supposed to be unlikely, are still far from being 
clear206. In the course of this thesis a proteomic combined with a genomic approach 
was applied to address chemoresistance in vivo and the involvement of selected 
proteins was studied in the chemoresistance relevant context of 3D tumor growth and 
in vitro resistance. 
 
Spheroid cultures of cancer cells better reflect characteristics of tumors than 
traditional monolayer cultures in terms of cell- cell contact and oxygen as well as 
nutrient supply. Furthermore, low-passage cancer cell lines recapitulate the 
properties of the original tumor cells more closely than commonly used standard cell 
lines that experience artificial selection processes and mutations over years of 
passaging. Fragmentation of Lamin A/C has been previously detected by 2D 
electrophoresis to occur in low passage colon cancer spheroids15. However, its role 
in 3D versus 2D tumor growth has not been clarified. The present work identified the 
lamin protein as a caspase-6-cleavage product in apoptotic cells of the spheroid. 
Similar caspase-dependent lamin cleavage was observed in monolayer cultures after 
serum withdrawal and further increased under hypoxic conditions, suggesting 
cleaved lamin as an indicator for apoptotic stress. 
A direct functional involvement of Hsp27 down-regulation in 5-FU chemoresistant 
colon cancer cells could not be detected by siRNA mediated knockdown of Hsp27 in 
chemosensitive colon cancer cells. However thymidylate synthase, a key enzyme in 
5-FU metabolism which has been previously described to be involved in 5-FU 
resistance was detected to be up-regulated in the 5-FU resistant colon cancer cells in 
vitro. 
Proteomic analysis of in vivo chemoresistance focused on a human prostate cancer 
(PC3) xenograft model which reflects acquired in vivo resistance towards metronomic 
cyclophosphamide treatment. Cells from in vivo resistant PC3 tumors were reisolated 
and reimplanted into SCID mice. Interestingly cells exhibited their resistant phenotyp 
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only in vivo but not in vitro78 whereas in vivo passaged control cells did not show 
resistance after reimplantation. Several known in vivo relevant escape mechanisms 
were experimentally excluded. Differences in drug efflux or changes in initial 
angiogenic potential of reimplanted resistant tumors were not detected. Vasculogenic 
mimicry as a potential escape mechanism was not evident. The sensitive and 
resistant tumor isolates were subject to 2D-DIGE followed by MALDI-TOF-TOF 
analysis of differential regulated protein spots. A total of 25 differences in protein 
expression between resistant and non resistant PC3 cells could be identified from 
which 4 protein spots were present in both resistant analyzed PC3 clones. Differential 
in vivo expression of these 4 candidates (annexin A3, thioredoxin containing protein 
5, cathepsin B, cytokeratin 19) was evaluated by western blot analysis from the 
corresponding tumor tissue. Cytokeratin 19 regulation was detected not to be 
associated with resistance by validation experiments. Thioredoxin containing protein 
5 was upregulated only in resistant xenografts by in vivo treatment. A truncated 
version of cathepsin B, a third protein spot identified in both resistant clones could be 
detected to be translocated into mitochondria in resistant clones whereas it stays 
cytoplasmic in corresponding parental PC3 cells. Annexin A3 was found to be 
upregulated in vitro and in vivo and protein levels further increased by metronomic 
cyclophosphamide treatment in vivo. 
Microarray analysis was performed of corresponding reimplanted PC3-xenografts 
derived from resistant and non resistant PC3 cells with and without CPA treatment 
(tumor harvesting 24h after CPA treatment). Data analysis revealed a strong 
influence of in vivo passaging onto the gene expression of PC3 xenografts. This 
strengthened the importance of taking in vivo environmental conditions into account. 
Several alterations in gene expression between resistant and non resistant PC3 
tumors could be identified. Hierarchical gene clustering led to first evidence that 
impaired interferon, calcium and TGFβ signaling might be involved in PC3 
chemoresistance in vivo. 
Furthermore microarray analysis revealed no significantly increased mRNA levels in 
case of cathepsin B which is consistant with protein analysis. Thus it would be 
interesting to focus on the truncated version of CatB which localizes to mitochondria 
of resistant PC3 cells. The regulation of TXNDC5 was also not reflected to a 
significant extent on mRNA level which leads to the conclusion that posttranslational 
mechanisms are involved in the significant protein regulation of TXNDC5 which have 
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been detected by proteomics and western blot analysis. In contrast, ANXA3 showed 
significant up-regulation on mRNA level in resistant compared to non resistant 
tumors. This makes ANXA3 a valid biomarker for prostate cancer resistance in vivo 
and can make it a potential target for in vivo knockdown studies in resistant PC3 
xenografts using siRNA application. 
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6. Appendix 
6.1. Tables 
Gene_Symbol Gene_Name Average A3 Average wt fold change A3 vs wt 
t-test/Anova A3 
vs wt 
NTS neurotensin 9.54 6.96 5.99 0.0002 
AMY2B amylase, alpha 2B (pancreatic) 9.65 8.10 2.93 0.0001 
MAGEC2 melanoma antigen family C, 2 7.89 6.34 2.92 0.0003 
SERPINB7 serpin peptidase inhibitor, clade B (ovalbumin), member 7 7.82 6.34 2.79 0.0002 
RSAD2 radical S-adenosyl methionine domain containing 2 10.66 9.42 2.36 0.0004 
ZNF204 zinc finger protein 204 pseudogene 7.78 6.55 2.35 0.0004 
CYP2B7P1 cytochrome P450, family 2, subfamily B, polypeptide 7 pseudogene 1 7.28 6.15 2.19 0.0012 
APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B 9.08 7.96 2.17 0.0006 
IL13RA2 interleukin 13 receptor, alpha 2 8.70 7.62 2.11 0.0059 
PDPN podoplanin 7.24 6.20 2.06 0.0000 
S100A2 S100 calcium binding protein A2 8.16 7.14 2.03 0.0007 
CDH12 cadherin 12, type 2 (N-cadherin 2) 5.29 9.65 -20.45 0.0000 
IFI44L interferon-induced protein 44-like 7.56 10.38 -7.07 0.0001 
CP ceruloplasmin (ferroxidase) 8.95 11.33 -5.21 0.0002 
GPR110 G protein-coupled receptor 110 9.07 11.14 -4.21 0.0005 
TCP11L2 t-complex 11 (mouse)-like 2 6.02 8.06 -4.12 0.0007 
KRT20 keratin 20 6.55 8.51 -3.91 0.0008 
GALNT3 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-T3) 4.95 6.90 -3.88 0.0002 
HSD17B13 hydroxysteroid (17-beta) dehydrogenase 13 4.55 6.41 -3.65 0.0045 
OAS1 2',5'-oligoadenylate synthetase 1, 40 7.68 9.54 -3.63 0.0004 
TMEM71 transmembrane protein 71 7.64 9.45 -3.50 0.0002 
ITGA10 integrin, alpha 10 7.82 9.59 -3.43 0.0001 
TTC6 tetratricopeptide repeat domain 6 5.69 7.46 -3.42 0.0021 
TSPAN8 tetraspanin 8 6.28 7.98 -3.25 0.0003 
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 7.48 9.17 -3.23 0.0002 
TFPI tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 6.65 8.34 -3.21 0.0132 
NPY1R neuropeptide Y receptor Y1 6.11 7.79 -3.21 0.0009 
RANBP3L RAN binding protein 3-like 6.04 7.71 -3.17 0.0006 
MX2 myxovirus (influenza virus) resistance 2 (mouse) 7.64 9.30 -3.17 0.0005 
TP53INP1 tumor protein p53 inducible nuclear protein 1 5.53 7.18 -3.14 0.0034 
TMEM56 transmembrane protein 56 5.04 6.69 -3.13 0.0004 
CDR1 cerebellar degeneration-related protein 1, 34kDa 7.92 9.54 -3.08 0.0009 
PLAT plasminogen activator, tissue 5.16 6.77 -3.06 0.0009 
IFI44 interferon-induced protein 44 5.07 6.67 -3.04 0.0012 
ABCA13 ATP-binding cassette, sub-family A (ABC1), member 13 8.57 10.16 -3.01 0.0007 
KDR kinase insert domain receptor (a type III receptor tyrosine kinase) 4.85 6.43 -3.00 0.0003 
SAMD9 sterile alpha motif domain containing 9 8.66 10.23 -2.97 0.0001 
SH2D1A SH2 domain protein 1A 6.01 7.57 -2.95 0.0002 
TRIM22 tripartite motif-containing 22 9.43 10.98 -2.94 0.0003 
MSTN myostatin 3.80 5.36 -2.94 0.0011 
IFIT3 interferon-induced protein with tetratricopeptide repeats 3 5.65 7.19 -2.90 0.0015 
SEMA3D sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D 5.34 6.87 -2.89 0.0003 
GLB1L3 galactosidase, beta 1-like 3 5.69 7.22 -2.89 0.0000 
IFIH1 interferon induced with helicase C domain 1 6.75 8.26 -2.85 0.0006 
C1orf161 chromosome 1 open reading frame 161 7.05 8.55 -2.83 0.0042 
IFITM1 interferon induced transmembrane protein 1 (9-27) 5.36 6.84 -2.79 0.0002 
C8orf57 chromosome 8 open reading frame 57 7.22 8.69 -2.75 0.0003 
IFI6 interferon, alpha-inducible protein 6 6.52 7.97 -2.72 0.0005 
TLR4 toll-like receptor 4 3.52 4.97 -2.72 0.0005 
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SLC26A5 solute carrier family 26, member 5 (prestin) 7.95 9.34 -2.62 0.0007 
C17orf60 chromosome 17 open reading frame 60 7.85 9.22 -2.59 0.0001 
TTN titin 7.28 8.65 -2.59 0.0004 
HERC6 hect domain and RLD 6 5.46 6.84 -2.59 0.0041 
C4orf18 chromosome 4 open reading frame 18 7.90 9.27 -2.58 0.0017 
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 4.22 5.59 -2.58 0.0013 
C14orf25 chromosome 14 open reading frame 25 7.62 8.99 -2.57 0.0007 
SAMD9L sterile alpha motif domain containing 9-like 7.10 8.46 -2.56 0.0003 
PCDHB10 protocadherin beta 10 9.13 10.48 -2.53 0.0007 
PCDHB4 protocadherin beta 4 8.40 9.74 -2.53 0.0025 
RELN reelin 6.46 7.80 -2.52 0.0111 
HIST2H2BE histone cluster 2, H2be 10.37 11.71 -2.52 0.0003 
COL12A1 collagen, type XII, alpha 1 7.23 8.54 -2.48 0.0004 
NDRG1 N-myc downstream regulated gene 1 6.33 7.65 -2.48 0.0002 
ZNF493 zinc finger protein 493 5.29 6.59 -2.46 0.0002 
HAPLN1 hyaluronan and proteoglycan link protein 1 4.54 5.84 -2.46 0.0003 
P2RY5 purinergic receptor P2Y, G-protein coupled, 5 6.72 8.01 -2.46 0.0132 
OR2B6 olfactory receptor, family 2, subfamily B, member 6 4.68 5.97 -2.45 0.0004 
CREB3L1 cAMP responsive element binding protein 3-like 1 7.24 8.53 -2.44 0.0019 
XK X-linked Kx blood group (McLeod syndrome) 8.60 9.89 -2.44 0.0002 
APOL6 apolipoprotein L, 6 6.33 7.61 -2.42 0.0119 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 6.38 7.65 -2.42 0.0002 
FAM130A2 family with sequence similarity 130, member A2 6.99 8.26 -2.41 0.0243 
ATP8A1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 6.03 7.29 -2.40 0.0002 
FAM177B family with sequence similarity 177, member B 6.37 7.61 -2.38 0.0011 
SLC25A27 solute carrier family 25, member 27 6.20 7.44 -2.37 0.0006 
CDC20B cell division cycle 20 homolog B (S. cerevisiae) 4.52 5.76 -2.36 0.0006 
ZNF788 zinc finger family member 788 5.11 6.33 -2.33 0.0000 
ABCA10 ATP-binding cassette, sub-family A (ABC1), member 10 8.21 9.43 -2.33 0.0008 
KRT81 keratin 81 7.47 8.69 -2.33 0.0010 
LANCL3 LanC lantibiotic synthetase component C-like 3 (bacterial) 7.11 8.32 -2.31 0.0019 
DNAH11 dynein, axonemal, heavy chain 11 6.77 7.98 -2.30 0.0006 
HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 10.47 11.67 -2.30 0.0005 
ZNF117 zinc finger protein 117 3.97 5.17 -2.30 0.0017 
CCDC146 coiled-coil domain containing 146 5.41 6.60 -2.29 0.0039 
ZNF528 zinc finger protein 528 5.88 7.08 -2.29 0.0005 
CFH complement factor H 8.35 9.54 -2.28 0.0006 
CGNL1 cingulin-like 1 6.10 7.29 -2.28 0.0009 
C2orf66 chromosome 2 open reading frame 66 3.77 4.95 -2.27 0.0012 
XAF1 XIAP associated factor 1 4.34 5.52 -2.27 0.0042 
MUC15 mucin 15, cell surface associated 7.83 9.01 -2.27 0.0016 
SATB1 SATB homeobox 1 5.51 6.69 -2.27 0.0003 
TMEM45A transmembrane protein 45A 8.29 9.47 -2.26 0.0024 
KIAA1244 KIAA1244 7.54 8.72 -2.26 0.0001 
TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 6.52 7.69 -2.25 0.0026 
ZNF253 zinc finger protein 253 5.29 6.45 -2.24 0.0064 
APOD apolipoprotein D 8.35 9.50 -2.22 0.0029 
PARP14 poly (ADP-ribose) polymerase family, member 14 7.03 8.18 -2.22 0.0005 
ZNF91 zinc finger protein 91 7.39 8.53 -2.21 0.0106 
STC2 stanniocalcin 2 7.33 8.46 -2.19 0.0006 
TBC1D8B TBC1 domain family, member 8B (with GRAM domain) 7.36 8.48 -2.18 0.0076 
KIAA1370 KIAA1370 7.23 8.34 -2.16 0.0021 
FER1L4 fer-1-like 4 (C. elegans) 7.15 8.26 -2.16 0.0005 
PGAP1 post-GPI attachment to proteins 1 8.45 9.55 -2.15 0.0035 
IFIT1 interferon-induced protein with tetratricopeptide repeats 1 5.59 6.68 -2.14 0.0042 
MUC5B mucin 5B, oligomeric mucus 8.33 9.43 -2.13 0.0018 
EHF ets homologous factor 5.22 6.31 -2.13 0.0021 
ELOVL2 elongation of very long chain fatty acids (FEN1 6.16 7.25 -2.13 0.0014 
FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) 10.81 11.89 -2.11 0.0003 
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ZNF841 zinc finger protein 841 9.06 10.14 -2.11 0.0004 
PPP4R1L protein phosphatase 4, regulatory subunit 1-like 7.61 8.69 -2.11 0.0011 
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 7.10 8.17 -2.10 0.0031 
ZNF83 zinc finger protein 83 8.49 9.56 -2.10 0.0026 
DDX60 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60 6.68 7.75 -2.10 0.0098 
ZNF625 zinc finger protein 625 8.17 9.23 -2.09 0.0003 
C5 complement component 5 8.55 9.61 -2.09 0.0012 
C10orf10 chromosome 10 open reading frame 10 7.10 8.16 -2.08 0.0234 
LGR5 leucine-rich repeat-containing G protein-coupled receptor 5 9.60 10.66 -2.08 0.0066 
STAT4 signal transducer and activator of transcription 4 9.06 10.11 -2.07 0.0003 
PCDHB9 protocadherin beta 9 6.45 7.50 -2.07 0.0010 
LOX lysyl oxidase 8.10 9.14 -2.06 0.0028 
SRGN serglycin 6.21 7.25 -2.06 0.0024 
VAV3 vav 3 guanine nucleotide exchange factor 7.01 8.05 -2.06 0.0002 
ZNF439 zinc finger protein 439 4.72 5.76 -2.05 0.0008 
LAMA4 laminin, alpha 4 6.41 7.44 -2.04 0.0011 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 5.99 7.02 -2.04 0.0010 
TTC18 tetratricopeptide repeat domain 18 5.51 6.54 -2.03 0.0005 
FRK fyn-related kinase 6.93 7.95 -2.03 0.0053 
TSPAN1 tetraspanin 1 7.40 8.42 -2.02 0.0020 
COL3A1 collagen, type III, alpha 1 7.35 8.36 -2.02 0.0009 
GBP2 guanylate binding protein 2, interferon-inducible 4.86 5.87 -2.02 0.0048 
DDX60L DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like 7.35 8.36 -2.02 0.0006 
RNF144B ring finger 144B 6.91 7.92 -2.01 0.0000 
HIST1H4H histone cluster 1, H4h 6.35 7.35 -2.01 0.0003 
KRTAP12-2 keratin associated protein 12-2 8.72 9.73 -2.01 0.0004 
SKIL SKI-like oncogene 7.42 8.43 -2.01 0.0100 
FLJ20184 hypothetical protein FLJ20184 6.35 7.35 -2.00 0.0085 
ZNF585B zinc finger protein 585B 5.95 6.95 -2.00 0.0005 
 
Table 6: Differentially expressed genes in PC3-A3 versus PC3-wt xenografts (2 fold regulation;T-Test: 
p< 0.05) 
 
 
Gene_Symbol Gene_Name Average 
PC3-A3 
Average 
PC3-D3 
fold change 
D3 vs A3 
t-test/Anova D3 
vs A3 
 PASD1   PAS domain containing 1  5.63 7.70 4.21 0.0000 
 RP6-
213H19.1  
 serine 5.96 7.36 2.64 0.0005 
 ZNF711   zinc finger protein 711  5.06 6.42 2.56 0.0065 
 ESM1   endothelial cell-specific molecule 1  4.84 6.06 2.33 0.0030 
 ZNF626   zinc finger protein 626  5.62 6.80 2.27 0.0007 
 CDC20B   cell division cycle 20 homolog B (S. cerevisiae)  4.52 5.61 2.14 0.0017 
 CDH12   cadherin 12, type 2 (N-cadherin 2)  5.29 6.39 2.14 0.0054 
 ANKRD30A   ankyrin repeat domain 30A  5.31 6.38 2.10 0.0025 
 ZNF788   zinc finger family member 788  5.11 6.16 2.07 0.0000 
 CALB1   calbindin 1, 28kDa  5.50 6.48 1.97 0.0103 
 MBNL3   muscleblind-like 3 (Drosophila)  5.46 6.43 1.96 0.0074 
 ZNF117   zinc finger protein 117  3.97 4.94 1.96 0.0003 
 GPC4   glypican 4  5.54 6.50 1.93 0.0004 
 SATB1   SATB homeobox 1  5.51 6.45 1.91 0.0006 
 ZNF486   zinc finger protein 486  5.56 6.49 1.91 0.0002 
 NCAM2   neural cell adhesion molecule 2  4.36 5.28 1.90 0.0001 
 RBM35A   RNA binding motif protein 35A  5.85 6.77 1.89 0.0013 
 ZNF429   zinc finger protein 429  4.57 5.47 1.86 0.0201 
 MPZL2   myelin protein zero-like 2  5.15 6.04 1.86 0.0012 
 ZNF66   zinc finger protein 66  5.82 6.71 1.85 0.0001 
 ZNF492   zinc finger protein 492  5.46 6.32 1.82 0.0118 
 SLC10A5   solute carrier family 10 (sodium 4.10 4.95 1.81 0.0191 
 ERV3   endogenous retroviral sequence 3 (includes zinc finger protein 
H-plk 
6.06 6.90 1.79 0.0001 
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 CDH13   cadherin 13, H-cadherin (heart)  8.13 8.96 1.78 0.0001 
 ZNF257   zinc finger protein 257  4.27 5.10 1.78 0.0370 
 PROKR1   prokineticin receptor 1  5.97 6.78 1.76 0.0002 
 BCAT1   branched chain aminotransferase 1, cytosolic  6.73 7.54 1.75 0.0005 
 ZNF625   zinc finger protein 625  8.17 8.97 1.75 0.0006 
 TFF1   trefoil factor 1  8.12 8.91 1.73 0.0000 
 MSTN   myostatin  3.80 4.59 1.72 0.0240 
 TMEM71   transmembrane protein 71  7.64 8.43 1.72 0.0148 
 GALNT14   UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 (GalNAc-T14)  
5.90 6.69 1.72 0.0001 
 SLC1A3   solute carrier family 1 (glial high affinity glutamate transporter), 
member 3  
6.54 7.30 1.70 0.0000 
 GLB1L3   galactosidase, beta 1-like 3  5.69 6.45 1.69 0.0011 
 ZNF91   zinc finger protein 91  7.39 8.14 1.68 0.0893 
 NTS   neurotensin  9.54 7.48 -4.18 0.0003 
 MAGEC2   melanoma antigen family C, 2  7.89 6.36 -2.89 0.0007 
 TCN1   transcobalamin I (vitamin B12 binding protein, R binder family)  9.64 8.34 -2.45 0.0005 
 PDPN   podoplanin  7.24 6.18 -2.09 0.0000 
 HCLS1   hematopoietic cell-specific Lyn substrate 1  7.93 6.91 -2.02 0.0007 
 IL1RAPL1   interleukin 1 receptor accessory protein-like 1  6.88 5.89 -1.97 0.0124 
 SSX8   synovial sarcoma, X breakpoint 8  7.42 6.47 -1.92 0.0093 
 SH2D1B   SH2 domain containing 1B  5.56 4.63 -1.91 0.0011 
 IL13RA2   interleukin 13 receptor, alpha 2  8.70 7.81 -1.86 0.0224 
 SCN3A   sodium channel, voltage-gated, type III, alpha subunit  5.97 5.10 -1.83 0.0103 
 SLAMF9   SLAM family member 9  6.82 5.97 -1.81 0.1041 
 APOL6   apolipoprotein L, 6  6.33 5.53 -1.75 0.0789 
 BMPR1B   bone morphogenetic protein receptor, type IB  7.71 6.95 -1.69 0.0036 
 
Table 7: Differentially expressed genes in PC3-D3 versus PC3-A3 xenografts (1.6 fold regulation;T-
Test: p< 0.05) 
 
 
Gene_Symbol Gene_Name Average A3 Average 
D4 
fold change 
D4 vs A3 
t-test/Anova D4 
vs A3 
 F3   coagulation factor III (thromboplastin, tissue factor)  7.01 8.93 3.79 0.0008 
 PASD1   PAS domain containing 1  5.63 7.51 3.68 0.0001 
 PRSS35   protease, serine, 35  6.58 7.81 2.35 0.0000 
 RBM35A   RNA binding motif protein 35A  5.85 6.93 2.10 0.0006 
 CDH13   cadherin 13, H-cadherin (heart)  8.13 9.19 2.08 0.0001 
 ZNF626   zinc finger protein 626  5.62 6.61 1.98 0.0007 
 SATB1   SATB homeobox 1  5.51 6.50 1.98 0.0003 
 ME1   malic enzyme 1, NADP(+)-dependent, cytosolic  8.23 9.20 1.96 0.0006 
 STAT1   signal transducer and activator of transcription 1, 91kDa  10.03 10.99 1.94 0.0002 
 MPZL2   myelin protein zero-like 2  5.15 6.10 1.94 0.0040 
 ZNF486   zinc finger protein 486  5.56 6.51 1.94 0.0022 
 CDC20B   cell division cycle 20 homolog B (S. cerevisiae)  4.52 5.47 1.93 0.0010 
 APOBEC3G   apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3G  
5.18 6.10 1.90 0.0049 
 C17orf60   chromosome 17 open reading frame 60  7.85 8.77 1.89 0.0012 
 CCDC141   coiled-coil domain containing 141  6.69 7.57 1.85 0.0042 
 ZNF788   zinc finger family member 788  5.11 5.99 1.84 0.0002 
 MBNL3   muscleblind-like 3 (Drosophila)  5.46 6.32 1.82 0.0006 
 GLB1L3   galactosidase, beta 1-like 3  5.69 6.54 1.80 0.0004 
 ZNF66   zinc finger protein 66  5.82 6.64 1.76 0.0006 
 TFF1   trefoil factor 1  8.12 8.93 1.76 0.0014 
 NOG   noggin  8.60 9.41 1.75 0.0042 
 ZNF625   zinc finger protein 625  8.17 8.97 1.75 0.0003 
 MGC9913   hypothetical protein MGC9913  5.87 6.67 1.73 0.0169 
 ODZ1   odz, odd Oz 6.64 7.43 1.73 0.0008 
 RP6-
213H19.1  
 serine 5.96 6.75 1.73 0.0007 
 CDH3   cadherin 3, type 1, P-cadherin (placental)  6.69 7.47 1.71 0.0007 
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 TGFB2   transforming growth factor, beta 2  6.09 6.86 1.70 0.0014 
 NTS   neurotensin  9.54 6.93 -6.10 0.0002 
 IL13RA2   interleukin 13 receptor, alpha 2  8.70 7.16 -2.91 0.0009 
 TCN1   transcobalamin I (vitamin B12 binding protein, R binder family)  9.64 8.17 -2.75 0.0009 
 SERPINB7   serpin peptidase inhibitor, clade B (ovalbumin), member 7  7.82 6.42 -2.64 0.0010 
 HCLS1   hematopoietic cell-specific Lyn substrate 1  7.93 6.69 -2.35 0.0000 
 NAV3   neuron navigator 3  7.53 6.44 -2.13 0.0005 
 IL1RAPL1   interleukin 1 receptor accessory protein-like 1  6.88 5.79 -2.12 0.0031 
 BMPR1B   bone morphogenetic protein receptor, type IB  7.71 6.62 -2.12 0.0016 
 PDE3A   phosphodiesterase 3A, cGMP-inhibited  7.52 6.45 -2.10 0.0003 
 PARP8   poly (ADP-ribose) polymerase family, member 8  7.48 6.48 -2.00 0.0033 
 SCN3A   sodium channel, voltage-gated, type III, alpha subunit  5.97 4.99 -1.98 0.0101 
 CHRM3   cholinergic receptor, muscarinic 3  8.97 7.98 -1.98 0.0001 
 ELMOD1   ELMO 6.53 5.55 -1.98 0.0023 
 KCNJ6   potassium inwardly-rectifying channel, subfamily J, member 6  6.98 6.01 -1.97 0.0007 
 FAM130A2   family with sequence similarity 130, member A2  6.99 6.02 -1.96 0.1060 
 KITLG   KIT ligand  9.58 8.65 -1.90 0.0481 
 MX1   myxovirus (influenza virus) resistance 1, interferon-inducible 
protein p78 (mouse)  
8.76 7.84 -1.90 0.0001 
 S100A2   S100 calcium binding protein A2  8.16 7.27 -1.86 0.0019 
 PLA2G4A   phospholipase A2, group IVA (cytosolic, calcium-dependent)  6.22 5.32 -1.86 0.0389 
 MAGEC2   melanoma antigen family C, 2  7.89 7.05 -1.80 0.0037 
 SCEL   sciellin  6.87 6.04 -1.78 0.0615 
 ARMCX3   armadillo repeat containing, X-linked 3  6.82 5.99 -1.78 0.0025 
 SLC14A1   solute carrier family 14 (urea transporter), member 1 (Kidd 
blood group)  
5.42 4.59 -1.78 0.0669 
 NR2F1   nuclear receptor subfamily 2, group F, member 1  9.25 8.43 -1.76 0.0037 
 SRPX   sushi-repeat-containing protein, X-linked  7.88 7.08 -1.74 0.0003 
 ORM2   orosomucoid 2  5.44 4.64 -1.74 0.0416 
 C13orf18   chromosome 13 open reading frame 18  6.45 5.66 -1.73 0.0006 
 CALCRL   calcitonin receptor-like  6.43 5.66 -1.71 0.1222 
 SCN2A   sodium channel, voltage-gated, type II, alpha subunit  5.70 4.93 -1.70 0.0251 
 HAS2   hyaluronan synthase 2  8.84 8.07 -1.70 0.0064 
 SSX1   synovial sarcoma, X breakpoint 1  4.83 4.08 -1.69 0.0294 
 
Table 8: Differentially expressed genes in PC3-D4 versus PC3-A3 xenografts (1.6 fold regulation;T-
Test: p< 0.05) 
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6.2. Abbreviations 
2D     twodimensional 
2DE    twodimensional electrophoresis 
3D    threedimensional 
5-FU    5-fluorouracil 
ABC    ATP-binding cassette  
Bcl-2    B-cell lyomphoma 2 protein 
Bcl-XL   Bcl-2 like protein 1 
BMDC   bone marrow derived cells 
COGA-12/G6  5-FU resistant COGA-12 cells 
COGA-12/NO  long term passaged COGA-12 cells 
CPA    cyclophosphamide 
DNA    deoxyribonucleic acid 
dTMP    deoxythymidine monophosphate 
FdUMP   fluorodeoxyuridine monophosphate 
HRPC    hormone resistant prostate cancer 
Hsp27   heat shock protein 27 
MALDI-TOF   matrix assisted laser desorption-time of flight  
Mcl-1    Induced myeloid leukemia cell differentiation protein Mcl-1 
MCS    multicellular spheroid  
MLH1    MutL homolog 1, colon cancer, nonpolyposis type 2 gene 
mRNA   messenger ribonucleic acid 
MS    mass spectrometry 
MTD    maximum tolerated dose 
RNA    ribonucleic acid 
rRNA    ribosomal ribonucleic acid 
TS    thymidylate synthase 
VEGF    vascular growth factor 
VEGFR2   vascular growth factor receptor 2 
GBM    glioblastoma multiform 
CSCs    cancer stem cells 
ALDH1   aldehyde dehydrogenase 1 
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DIGE    differential in gel electrophoresis 
LC-MS   liquid chromatography mass spectrometry 
SCID    severe combined immuno deficiency 
4-HOO-CPA   4-hydroperoxy-cyclophosphamide 
PC3    human prostate carcinoma cell line 
PC3-wt   wild type PC3 cell 
PC3-A3   reisolated in vivo passaged PC3 cells 
PC3-D3   reisolated in vivo resistant PC3 cells  
PC3-D4   reisolated in vivo resistant PC3 cells 
4-HO-CPA   4-hydroxy CPA 
CD31    cluster of differentiation 31 
siRNA    small interfering ribonucleic acid 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end 
labelling 
zVAD-fmk carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- 
fluoromethylketone (pan caspases inhibitor) 
zVEID-fmk carbobenzoxy-valyl-glutamyl -[O-methyl]- isoleucyl-
aspartyl -[O-methyl]- fluoromethylketone (caspases 6 
inhibitor) 
CK18 cytokeratin 18 
RT-PCR reverse transcriptase PCR 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
EGF(R) epidermal growth factor (receptor) 
CD71 cluster of differentiation 71 (transferrin receptor) 
hEGFR human epidermal growth factor receptor 
MS/MS tandem mass spectrometry 
PMF peptide mass fingerprint 
CK19 cytokeratin 19 
MCF-7 breast carcinoma cell line 
pI isoelectric point 
CatB cathepsin B 
kDa kilo Dalton 
TXNDC5 thioredoxin domain containing protein 5 
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ANXA3 Annexin A3 
RMA robust multichip analysis 
GABRE gamma-aminobutyric acid (GABA) A receptor, epsilon 
STAT1 signal transducer and activator of transcription-1 
SLC7A6 Solute carrier family 7 member 6 
MBNL-3 muscleblind-like 3  
ZNF468 zinc finger protein 486 
TGFB2 transforming growth factor, beta 2 
CD274 programmed cell death 1 ligand 1 
TNFAIP6 tumor necrosis factor alpha-inducible protein 6 
GPR126 G protein-coupled receptor 126 
PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
MPHOSPH6 M-phase phosphoprotein 6 
PASD1 PAS domain containing protein 1 
GALNT4 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 4 
BMPR1 bone morphogenetic protein receptor type1 
CHRM3 cholinergic receptor, muscarinic 3 
KCNJ6 potassium inwardly-rectifying channel, subfamily J, 
member 6 
Mx1 myxovirus (influenza virus) resistance protein 1 
PDGFD platelet derived growth factor D 
F3 tissue factor gene symbol 
TF tissue factor protein 
P0 acidic ribosomal protein P0 
tRNA transfer ribonucleic acid 
15-PGDH 15-hydroxyprostaglandin dehydrogenase 
HSF heatshock transcription factor 
dTTP deoxythymidine triphosphate 
DU145 human prostate cancer cell line 
HSPD1 heat shock 60kDa protein 1 
Trx thioredoxin 
PDI protein disulfide isomerase 
IL13RA2 interleukin 13 receptor, alpha 2 
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S100A2 S100 calcium binding protein A2 
TP53INP1 tumor protein p53 inducible nuclear protein 1 
LOX lysyl oxidase 
EMP-2 epithelial membrane protein 2 
COX-2 cyclooxygenase-2 
Sox-10 SRY (sex determining region Y)-box 10 protein 
PLC phospholipase C 
PIP2 phosphatidylinositol-4,5-bisphosphate 
OAS3 2'-5'-oligoadenylate synthetase 3 
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6.3. Publications 
6.3.1. Original Papers 
L.Gaedtke*, L.Thoenes*, C.Culmsee, B. Mayer, E. Wagner. Proteomic Analysis 
Reveals Differences in Protein Expression in Spheroid versus Monolayer Cultures of 
Low-Passage Colon Carcinoma Cells, J. Proteome Res., 6 (11), 4111 -4118, 2007 
 
L.Thoenes, M.Hoehn, R. Kashirin, M.Ogris, G.J.Arnold, E.Wagner, M. Guenther. In 
vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy, 
resubmitted Manuscript 
6.3.2. Review Article 
L.Thoenes, M.Guenther. Novel approaches in anti-angiogenic treatment targeting 
endothelial F-actin: a new anti-angiogenic strategy?, Current Opinion in Molecular 
Therapeutics, 10 (6), 579-590, 2008 
6.3.3. Poster Presentations 
L.Thoenes, M.Guenther, M. Ogris, G.J. Arnold, E.Wagner, Escape mechanisms in 
metronomic cyclophospamide therapy in vivo (HUPO world congress, Amsterdam, 
2008) 
 
M.Guenther*, L.Thoenes*, M.Ogris, G.J. Arnold, E. Wagner, Chemoresistance of 
prostate cancer cells in metronomic cyclophosphamide therapy in vivo (Integrative 
cancer genomics Meeting, Munich, 2008) 
 
L.Thoenes*, L.Gaedtke*, C.Culmsee, B. Mayer, E. Wagner. Proteome differences in 
spheroid versus monolayer cultures of low passage colon carcinoma cells (Capri 
Science Conference: Cancer therapeutcis-the road ahead, Capri, 2007) 
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